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1. LIST OF ABBREVIATIONS 
 
- PRL: Prolactin 
- kDa: kilodalton 
- GH: Growth Hormone 
- hPL: Human Placental Lactogen 
- REM: Rapid Eye Movement 
- GnRH: Gonadotropin Releasing Hormone 
- TRH: Thyrotropin Releasing Hormone 
- VIP: Vasoactive Intestinal Peptide 
- LH: Luteinizing Hormone 
- MRI: Magnetic Resonance Imaging 
- DA: Dopamine Agonists 
- D2R: Dopamine 2 Receptor  
- PRL-R: PRL Receptor 
- CSF: Cerebrospinal Fluid 
- NFPA: Non – Functioning Pituitary Adenomas 
- PD: Parkinson’s Disease 
- ICDs: Impulse Control Disorders 
- BBB: Blood-Brain Barrier 
- MDR1: Multidrug resistance 1 gene 
- SNPs: Single Nucleotide Polymorphisms 
- P-gp: P-glycoprotein 
- RLS: Restless Legs Syndrom 
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2. INTRODUCTION/BACKGROUND 
2.1 Epidemiology of hyperprolactinemia 
The prevalence of hyperprolactinemia in women with secondary amenorrhea or 
oligoamenorrhea is estimated to be 10% to 25%. Hyperprolactinemia is noted in 
approximately 30% of women with galactorrhea or infertility and in 75% of those with both 
amenorrhea and galactorrhea (1, 2). Hyperprolactinemia is present in 16% of patients who 
have erectile dysfunction and in approximately 11% of patients who have oligospermia (3). 
 
2.2 Secretion of Prolactin 
Prolactin is a protein (198 amino acids with a molecular mass of 21500 daltons) synthesised 
in lactotrope cells (~ 20% of anterior pituitary cells). In pregnancy lactotrope cell hyperplasia 
is induced by estrogen (especially the last two trimesters and in lactation) (4). PRL is secreted, 
in a pulsatile manner, reaching its peak levels in the morning and has also a circadian 
fluctuation with higher levels during non–rapid eye movement (REM) sleep (5). It is inhibited 
by hypothalamic dopamine and transported to the pituitary by portal vessels, mediated 
through the dopamine type 2 receptors (D2R) and stimulated from thyrotropin releasing 
hormone (TRH) and vasoactive intestinal peptide (VIP). The normal adult serum PRL levels 
are below 25 ng/ml and 20 ng/ml in women and men, respectively, as detected with the more 
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2.3 Role and action of prolactin 
The main role of PRL is to induce and maintain lactation, decrease reproductive function and 
libido, so that maternal lactation is sustained and not interrupted by a new pregnancy. PRL 
suppresses hypothalamic GnRH and pituitary gonadotropin secretion and impairs gonadal 
steroidogenesis in both women and men. In the ovary, PRL directly blocks folliculogenesis 
leading to hypoestrogenism and anovulation. The luteolytic effect of PRL leads to a shortened 
or inadequate, luteal phase of the menstrual cycle. In men, attenuated LH secretion leads to 
low testosterone levels and decreased spermatogenesis (4). 
The PRL receptor (PRL-R) is a transmembrane protein, encoded by a single gene on 
chromosome 5 (6-8) and is mainly present in the mammary gland and the ovary, but also in 
multiple tissues (pituitary gland, thymus, spleen, liver, pancreas, kidney, adrenal gland, 
uterus) (9). Interestingly, PRL receptors are also found in several areas of the CNS (10, 11). 
 
2.4 Definition and classification of prolactinomas 
Prolactin hypersecretion is the most common endocrine abnormality due to hypothalamic-
pituitary disorders and prolactinomas, the tumours arising from lactotrope cells of the anterior 
pituitary accounting for about 40% of all pituitary tumours. Microprolactinomas, as for all the 
pituitary adenomas, are classified as <1 cm in diameter and do not usually invade the 
parasellar region, whereas macroprolactinomas have a diameter >1 cm and may be locally 
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Figure 1: Micro- and macroadenoma, sagittal MRI views (courtesy of Prof. Dr. Schopohl). 
 
Their annual incidence is considered to be 6-10 cases per million population (12). Some more 
recent data from a study conducted in a tightly defined geographic area in Liege in Belgium, 
show a much higher prevalence at 55 per 71000 (775 per million) inhabitants (1). Their 
frequency depends on age and sex, with increased preference in females between 20 and 50 
years old, when the ratio between the sexes is estimated to be 10:1. After the fifth decade of 
life their frequency seems to be equivalent in both sexes (13, 14). 
The vast majority of the prolactinomas are benign adenomas. Approximately 50 malignant 
prolactinomas have been described (15, 16). The presence of metastatic lesions is the most 
important differential diagnostic tool from the aggressive prolactinomas which are a more 
frequent finding. The prognosis of malignant prolactinoma is poor, with a 1-year prevalence 
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2.5 Clinical features and differential diagnosis of prolactinomas 
The basis of the clinical manifestations of prolactinomas is the hyperprolactinemia and the 
tumour that can present with neurological signs. Collectively, the above mentioned PRL 
actions lead to various forms of primary or secondary hypogonadism in both genders. 
Women present with the classic amenorrhea-oligomenorrhea with anovulation, galactorrhea, 
and infertility syndrome but when hyperprolactinemia develops prior to menarche in children 
or adolescents, results in primary amenorrhea. The galactorrhea is considered abnormal if it 
persists for longer than 6 months after discontinuation of breastfeeding. It occurs in the 
majority of women with prolactinomas and is much less common in men. It may come 
spontaneously or be elicited by nipple pressure, present only transiently or intermittently. 
The necessity of measuring PRL levels in patients with unexplained preliminary or secondary 
amenorrhea in the clinical practise should be emphasised, due to the fact that 
hyperprolactinemia may be present even in the absence of galactorrhea. Some other 
symptoms could be weight gain, decreased libido or mild hirsutism (4, 17, 18). 
In men, excess PRL presents with hypogonadism, diminished libido, infertility and rarely 
galactorrhea and gynecomastia. Gonadotropin suppression from PRL leads to reduced 
testosterone, impotence, and oligospermia. If the disorder is longstanding, decreased beard 
growth and reduced muscle mass can be present as secondary effects of hypogonadism (4, 17, 
18). 
In macroprolactinomas, the diagnosis is often made due to local pressure. Neurologic 
symptoms (headache and visual field defects such as bilateral hemianopsia, initially of 
superior quadrants) are common in patients who have macroadenomas or giant adenomas and 
also in men, due to the delayed diagnosis, whereas atypical clinical manifestations (e.g. 
diplopia, cranial nerve paralysis) are most frequent in aggressive or malignant forms. 
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Furthermore, some non-specific symptoms of anterior pituitary deficits could be present in 
cases of macroadenomas. 
 
In cases of pronounced hypoestrogenemia, osteopenia should be considered. This has recently 
been considered a new indication for early treatment of prolactinoma (19). The mechanism of 
the negative effect of PRL excess remains rather vague, but some in vitro and in vivo data 
suggest a predominant role for estrogen deficiency (20). 
The prolactin measurement should be considered in one of the following conditions: (18)  
- Galactorrhea 
- Enlarged sella turcica 
- Suspected pituitary tumour  
- Hypogonadotropic hypogonadism including unexplained amenorrhea or unexplained male 
hypogonadism or infertility 
As far as the diagnosis of hyperprolactinemia is established (basal, elevated fasting morning 
PRL levels or levels on several different occasions), the clinician should carefully exclude 
secondary causes using the diagnostic tools (careful clinical history, physical examination, 
pregnancy test, routine biochemical analysis for kidney and liver function and TSH and T4 
determination (19). Some of the most common causes of elevated PRL levels that must be 
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Table 1: Causes of hyperprolactinemia (17, 21) 
 
Physiological Hypothalamic diseases Pituitary diseases Drugs 
- Pregnancy 
- Lactation 






- Infiltrative diseases  
- Cranial irradiation 
-Vascular abnormalities 
- Pseudotumour cerebri 
 
- Functioning and 
non-functioning 
adenomas 




- Primitive tumours 
and metastasis 












In general, serum prolactin levels parallel tumour size. PRL values between the upper limits 
of normal and 100 ng/ml are usually due to drugs, hormones or functional (idiopathic) causes 
but can also be caused by microprolactinomas. Most patients with PRL levels over 150 ng/ml 
will have a prolactinoma. Macroprolactinomas are typically associated with levels of over 250 
ng/ml and in some cases over 1000 ng/ml, whereas in recent studies levels greater than 500 
ng/ml are referred to as diagnostic (22). Nevertheless, the clinician should be aware that 
prolactinomas can present with variable elevations in PRL and there may be discordance 
between tumour mass and PRL value (19). 
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Two potential pitfalls in the biochemical diagnosis of hyperprolactinemia should be taken into 
consideration, when PRL is measured: macroprolactin and ‘‘hook effect.’’ 
 
Macroprolactin is a complex of PRL with an IgG antibody, with reduced bioactivity and is not 
detected by all PRL assays. Its reduced clearance is a cause of potential false-positive results 
(23). For confirmation of macroprolactinemia, polyethylene glycol precipitation and 
ultrafiltration are the most practical methods (24, 25). 
 
The “hook effect” can be observed in some cases of giant prolactinomas. The extremely high 
PRL levels cause antibody saturation in the two-site assays, resulting in false low levels. This 
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artefact can be eliminated by 1:100 dilutions of serum samples. It is recommended to exclude 
the “hook effect” in all new patients who have a large macroadenoma with unexpectedly 
normal to mildly elevated PRL levels (26). 
 
After other common causes have been excluded, patients should be investigated for possible 
structural pathology in the hypothalamo-pituitary region. Gadolinium-enhanced MRI is 
currently the radiological investigation of choice (27) and increases the detection of 
microadenomas. CT with intravenous contrast is the second available option in cases where 
MRI is contra-indicated or inappropriate but remains less effective than MRI in diagnosing 
small adenomas. 
 
However, it should be noted that microadenomas are present in 10–20% of the normal 
population, as judged by autopsy studies. On the other hand, a normal MRI scan does not 
completely exclude a microadenoma <2 mm in diameter or a hyperplasia (28, 29). 
 
The potential problem of differential diagnosis between a large nonsecreting tumour causing 
modest PRL elevations and a true prolactinoma should be lost by the possible response to the 
dopamine agonist treatment. Normalisation of PRL levels combined with reduction of 
adenoma size leads to the diagnosis of prolactinoma. 
 
Many functional tests have been suggested as diagnostic tools in the evaluation of 
hyperprolactinaemia, including administration of TRH, L-dopa and insulin-induced 
hypoglycemia but are of no clinical use. Hence, the only reliable diagnostic algorithm of a 
prolactinoma should be the analysis of basal PRL values, the imaging of the pituitary and the 
exclusion of other causes as outlined above (29, 30). 
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The diagnostic algorithm should also include visual-field examination (e.g. computerised 
Goldman perimetry) and examination for hypopituitarism, mainly for patients with 
macroadenomas (19). 
 
The diagnosis of idiopathic hyperprolactinemia is made by the exclusion of known causes of 
hyperprolactinemia in the setting of a normal pituitary MRI. Some of these patients may have 
small microadenomas below MRI sensitivity (~2 mm). 
 
2.6 Management of prolactinomas 
The primary goals of treatment in prolactinomas are: 
- Satisfactory control of PRL hypersecretion, in order to restore gonadal function and 
sexual function 
- Reduction of the tumour mass 
 
The final decision for treatment should take into consideration that approximately 90% of 
microprolactinomas remain stable during the follow-up in 4 to 6 years (31-33). 
Medical, and sometimes also surgical therapy, is always advisable for all macroadenomas, 
whereas the indications for treating microadenomas depend on the symptoms. According to 
current guidelines (34), premenopausal women with normal cycles and tolerable galactorrhea 
and postmenopausal women with tolerable galactorrhea who have microprolactinomas may 
be reassured and not treated. These women must be followed clinically with periodic PRL 
measurements. The increase of PRL levels, or the neurological symptoms of mass 
development, should be an indication for a MRI study. 
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Table 2: Indications for therapy (19, 34, 35) 
 
Absolute indications Relative indications 
- Mass effects 
- Hypopituitarism 
- Visual field defects 
- Cranial nerve deficits 
- Headaches 
- Effects of hyperprolactinemia 
- Hypogonadism 
- Amenorrhea or oligomenorrhea 
- Infertility 
- Impotence 
- Osteoporosis or osteopenia 
- Bothersome hirsutism 
- Bothersome galactorrhea 
 
Figure 3: Indications for treatment: an algorithm (Adopted from Casanueva et al., 2006) (19).  
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2.6.1 Medical treatment with dopamine agonists 
There are five dopamine receptors already described in the literature, all of which are 
members of the superfamily of G protein-coupled receptors. The regulation of prolactin is 
mediated by the D2 receptor (encoding gene localised in chromosome 11q). D2R-mRNA 
seems to be expressed in the substantia nigra, ventral tegment area, hippocampus, caudal 
putamen, nucleus accumbens and olfractory tubercle but is also expressed in high levels in 
anterior pituitary (36). 
 
The primary therapy is medical treatment with dopamine agonists (DA) such as bromocriptine 
and cabergoline. These drugs not only normalise PRL levels but can also significantly reduce 
the volume of the tumour in most patients and extensive experience has demonstrated their 
utility in treating prolactinomas of all sizes (19). These agents bind to the dopamine D2 
receptors on pituitary lactotrope cells, resulting in a decrease in synthesis and release of PRL 
(37, 38). However, none of the dopamine agonists are absolutely specific for any dopamine 
receptor subtype (36). 
The most common used dopamine agonists, bromocriptine and cabergoline, bind to the D2 
receptors, whereas quinagolide, pergolide and lisuride are not that widely used, and are 
preferred as an alternative therapy in cases of intolerance/resistance of bromocriptine or 
cabergoline. While all three lower serum PRL on oral administration and also reduce tumour 
size, they have different affinity for D2 receptors and plasma half-life. Cabergoline has the 
highest affinity and greatest selectivity for D2 receptors. The half-lives of cabergoline, 
quinagolide and bromocriptine are approximately 65 h, 24 h and 8–12 h, respectively (39). 
 
Bromocriptine, a short acting ergot alkaloid, was developed in the 1970s as the first DA to be 
introduced for the prolactinomas and there is plenty of data regarding its safety, efficacy and 
mechanism of action. The useful clinical experience collected over these years shows that this 
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medication is efficient and normalises PRL levels in 80–90% of patients with 
microprolactinomas and nearly 70% of those with macroprolactinomas, having also a 
significant effect on the reduction of the tumour mass (40-42). 
 
Therapy with bromocriptine (tablet of 2,5-5 or 10 mg) is initiated with an oral dose of 0,625–
1,25 mg daily and increased by 1,25 mg at weekly intervals until a dose generally of 2,5 mg 
twice or thrice daily is reached (max. dose 15 mg/day) (19). Starting with a low dose and 
gradually increasing the dose over days and weeks until the PRL level is suppressed to the 
normal range, could increase tolerance and diminish possible side effects. 
Cabergoline is a long active and more selective ergoline derivative dopamine agonist of D2 
receptors. The drug, due to a longer half life, can suppress PRL for longer than 14 days after a 
single oral dose. 
Cabergoline (tablet of 0,5 or 1 mg) should be started at a dosage of 0,25 mg once or twice per 
week and increased to 0,5 or 1 mg twice weekly. Doses more than 3 mg per week are rarely 
necessary. The final goal of normoprolactinemia and resumption of normal gonadal function 
is achieved in approximately 80% of patients with microadenomas; galactorrhea improves or 
resolves in 90% of patients (4). In the case of macroprolactinomas, the therapy response is 
lower (~70%). Cabergoline has been proved as efficient and better tolerated in most patients 
previously intolerant or resistant to bromocriptine (4) and according to the most recent 




Figure 4: Macroprolactinoma after 2 years 
with DA therapy (courtesy of Prof. Dr. 
Schopohl). 
 - 20 -
Resistance to dopamine agonists, defined as a failure to normalise PRL levels and /or reduce 
tumour  size, is reported in 10-15 % of patients (35). The reasons for this phenomenon remain 
unclear and possible mechanisms have been speculated such as reduction of dopaminergic 
binding sites or polymorphisms of the D2 receptor gene (43-45). An increase of cabergoline 
dose up to 11 mg/week is suggested, under regular echocardiographic control for the potential 
risk of cardiac valvular regurgitation (34). 
 
2.6.2 Surgical treatment and radiotherapy 
The effective medical treatment in restoring normal PRL levels and reducing the tumour size, 
without the possible complications of a pituitary insufficiency, has limited the indications for 
surgical resection of prolactinomas only to rare cases (19, 35). The transsphenoidal approach 
is considered to be the standard surgical treatment (46). Complications from transsphenoidal 
surgery are quite infrequent, including mortality, cerebrospinal fluid (CSF) rhinorrhea, 
pituitary insufficiency etc. 
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Radiotherapy is nowadays very rarely used and is associated with significant incidence of 
major side-effects, including pituitary insufficiency, damage to the optic nerve, neurological 
dysfunction and increased risks of stroke and secondary brain tumours. It should be reserved 
for patients in whom medical and surgical therapy have failed (18). 
 
2.6.3 Side effects of DA 
The most common side effects are gastrointestinal (nausea, dyspepsia, abdominal pain), 
postural hypotension, dizziness and headache. 
 
Figure 5: Transsphenoidal resection of 
pituitary mass via the endonasal approach, 
(adopted from Fahlbusch et al., 1992). 
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Bromocriptine can cause gastrointestinal (nausea and vomiting), cardiovascular and 
neurologic side effects. These can be minimised by an incremental dosage schedule and 
taking tablets with or after the meal at night. The most frequent neurologic adverse effects are 
headache and drowsiness. Moreover, dyskinesias are well recognised effects of high-dose 
treatment. Reversible pleuropulmonary changes and retroperitoneal fibrosis have been 
reported in patients treated with a high dose of bromocriptine for Parkinson’s disease; 
however, because the effects seem to depend on dose, they are unlikely to occur at the low 
doses used for prolactinoma. 
Side effects of cabergoline are similar to those reported for other dopamine agonists but are 
generally less frequent, less severe, and of shorter duration; in fact, withdrawal of this drug 
because of side effects is reported in less than 3% of patients. The most common adverse 
event is nausea or vomiting, followed by headache and dizziness. Recently, several studies 
have been published describing increased prevalence of cardiac valve regurgitation in patients 
who were treated with cabergoline. However, regurgitation was only an echocardiographic 
finding and was not accompanied by symptoms. Echocardiography should be therefore 
recommended to all patients with hyperprolactinemia planned to be treated with or are under 
cabergoline therapy (47). 
According to the latest consensus statement of February 2011 (34) and a recent meta-analysis 
of randomised controlled trials (48), cabergoline seems to be more effective than 
bromocriptine in terms of normalising prolactin levels and menstruation, probably due to its 
higher affinity for dopamine receptor binding sites. Furthermore, cabergoline seems to be 
superior and more tolerable in terms of nausea and vomiting, increasing therefore the drug 
compliance. 
 - 23 -
2.6.3.1 Neuropsychiatric side effects of DA in different patient groups 
The loss of dopaminergic neurons in Parkinson’s disease is characterised by motor, cognitive, 
behavioural and autonomic symptoms. The dopamine replacement therapies with dopamine 
agonists are very effective in treating the symptoms but have recently been associated with de 
novo onset of adverse events, which are, amongst others, impulse control disorders (ICDs) 
such as pathological gambling, compulsive shopping, hypersexuality and binge eating. These 
symptoms are generally characterised by the maladaptive nature of the preoccupations and the 
inability to control these urges (49) and they mainly have a de novo onset after the initiation 
of dopamine replacement therapy. Problems related to pathological gambling have been 
described in Parkinson patients with a varying frequency from 3,4 % up to 6,1 % (50), 
significantly increased beyond that of the general population. In nearly all cases, the patient 
had no gambling history and in some studies the dopamine agonist therapy was adjunctive 
(51), whereas only rare cases have been associated with carbidopa or levodopa monotherapy 
(52). Recent data from a multicentre study of 3090 patients with PD in the USA revealed a 
much higher occurrence of ICDs up to 13,6% (53). 
 
However, symptoms such as pathological gambling, compulsive shopping and hypersexuality 
tendency have been also described in patients with Restless Legs Syndrome (RLS) who are 
treated with dopamine agonists, but the prevalence is less established (54, 55). 
 
Regarding the patients with prolactinomas, where the medical treatment of choice are also the 
dopamine agonists, there is a lack of published data. Up to date, there are two case reports that 
describe cabergoline-induced gambling under a low dose (<1 mg weekly) of cabergoline as 
treatment for microprolactinoma (56, 57). Both patients had a free psychiatric and gambling 
history and the symptoms ceased after the withdrawal of the medication. In one of these two 
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patients, gambling was also combined with excessive libido and hypersexual activities that 
concluded to divorce proceedings (56). 
 
2.6.4 The role of the MDR1 transporter (coded by the ABCB1 gene) and the action of 
cabergoline 
The pituitary gland maintains its anatomical and functional connections with the brain though 
sitting outside the blood-brain barrier. Despite the lack of anatomical connection of the 
anterior pituitary with the hypothalamus, there is a functional connection with this part of the 
brain via hypothalamic dopaminergic neurons that release dopamine which, via a system of 
hypophyseal portal vessels, act on the endocrine cells of the anterior lobe to inhibit the 
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Figure 6: The pituitary gland and its anatomical and functional connections. Abbreviations: AHA, anterior 
hypothalamic area; AR, arcuate nucleus; DMN, dorsomedial nucleus; MB, mammillary body; ME, median 
eminence; MN, medial nucleus; OC, optic chiasm; PHN, posterior hypothalamic nucleus; POA, preoptic area; 
PVN, paraventricular nucleus; SCN, suprachiasmatic nucleus; SO, supraoptic nucleus; VMN, ventromedial 
nucleus (adopted from: Endocrinology, An Integrated Approach, Stephen Nussey and Saffron Whitehead. St. 




The central side effects of the systematically administered cabergoline and dopamine agonists 
in general, depend on their ability to pass the blood-brain barrier (BBB). The concentration of 
the medication into the central nervous system has been found to be actively controlled from 
transporters that are expressed at the luminal membrane of the endothelial cell-lining that is 
formed from small blood capillaries. One of these molecules that actively (upon ATP) bind 
their substrates transporting them out of cells back into the blood circulation against a 
concentration gradient, acting as a gatekeeper in controlling the passage of substances 
between the blood and the brain, is a P-glycoprotein (P-gp), encoded by the ABCB1 gene (or 
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multidrug resistance gene - MDR1) located on chromosome 7. Cabergoline has been found 
recently to be a substrate of this transporter (Uhr et al., 2008 unpublished data). 
 
However, P-gp has been found to be localised, apart from in the brain, in many different 
tissues such as gonads, bone marrow, liver and small intestine as well as in the fetus and its 
function and anatomic localisation suggests it acts as a protective barrier to keep potentially 
toxic P-gp substrate compounds out of the body limiting tissue exposure (58). 
 




Extended studies have revealed that genetic variants in the ABCB1 transporter P-gp correlate 
with different intracerebral concentrations of antidepressants and therefore clinical response 
(59). To date, there are more than 95 SNPs that have been identified. More specifically, single 
nucleotide polymorphisms (SNPs) have been tested and among others, the following 4 SNPs 
have been associated with an altered expression and function of the P-gp: rs045642, 
rs2032582, rs2032583 and 2235015 and were therefore selected for genotyping in our study. 
In the recent study of Uhr et al. (59) there was a clear difference in the genotype distribution 
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of rs2032583 and rs2235015 between remitters and non-remitters (for treatment with 
antidepressants acting as substrate for the P-gp) in favour of C- and T-carriers respectively. 
The study of Kato et al. (60) led to the conclusion that the C-variant of rs1045642 and the G-
variant of rs2032582 were also linked to a higher expression and function of P-gp, resulting in 
a poor treatment response and decreased remission rates. 
 
Figure 8: P-gp: a drug efflux pump in the brain's vascular endothelium. 
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3. AIM OF THE PROJECT 
 
The aim of our project was to investigate the genetic predictors of the side effect profile of 
treatment with dopamine agonists in prolactinoma patients.  
We hypothesised that the neuropsychiatric side effects of DA therapy in particular (not only 
in prolactinoma, but also in other patient groups) are dependent on the concentration of 
dopamine agonists in the brain. 
The intracerebral concentration of DA (and especially cabergoline) in the brain is controlled 
from the MDR1 transporter P-gp at the blood-brain-barrier level as shown by our collaborator 
Manfred Uhr and colleagues in a mouse model (unpublished data). If the function of P-gp is 
reduced, lower is the amount of cabergoline that is removed from the brain tissue and the 
higher remains its concentration in the brain. 
Genetic variants of the encoding gene ABCB1 (or MDR1 gene), among other SNPs rs045642, 
rs2032582, rs2032583 and 2235015, control its expression and function, leading to an 
individual predisposition to develop some neuropsychiatric side effects. 
In 9 studies up to now, the role of these genetic variants in the remission rate under 
antidepressants-substrates of P-gp is being examined. In 6 of them, a significant genotype and 
remission interaction has been established (61). 
 
Hence, we hypothesised that the genetic variants of the MDR1 transporter, namely the 
ABCB1 gene variants, will equally predict the occurrence of neuropsychiatric side effects in 
patients treated with cabergoline and/or DA. 
 
To elucidate this question, we designed a prospective, diagnostic study in prolactinoma 
patients (and NFPA controls) treated with DA. Patient’s neuropsychiatric side effects were 
investigated on the basis of questionnaires and self rating. 
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Additionally, we collected blood and performed genetic analyses, to determine the potential 
associations between the ABCB1 gene variants and the number of neuropsychiatric side 
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4. SUBJECTS AND METHODS 
4.1 Type of the study 
This study is a case-control study. In a cross-sectional approach, we prospectively enrolled 92 
patients during a period of two years between December 2008 and January 2011 (including 
the planning phase, recruitment of patients, acquisition of the data, the analysis and writing of 
the results). As a clinical control group, patients with non-functioning pituitary adenomas 
(n=60) were recruited at the same clinic. 
 
4.2 Patient sample 
Ninety two patients with prolactinomas, treated at the Endocrine Outpatient Unit of the Max 
Planck Institute of Psychiatry (23 male and 69 female, mean age at study time 49,2 ± 13,8 
years, mean BMI 25,6 ± 6,9 kg/m²), were enrolled. Patients were identified through the 
electronic database of the Institute and agreed to participate in this study. Questionnaires were 
sent to these patients and they were asked to return them in prepaid envelopes. Written 
informed consent was obtained from all the participants in the study and the study was 
approved by the Ethics Committee of the Ludwig-Maximilian-University of Munich. Clinical 
characteristics of the subjects were collected with regard to disease history, tumour 
characteristics, previous and present therapy and comorbidities as well as present complaints. 
Comorbidities were diagnosed according to the respective guidelines. In the case of missing 
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4.3 Inclusion and exclusion criteria 
Inclusion criteria 
(i) Patients over 18 years of age. 
(ii) Diagnosis of a prolactinoma (micro- or macroprolactinomas). 
(iii) Written informed consent. 
 
Exclusion criteria 
(i) Patients under 18 years of age. 
(ii) Patients unwilling to participate. 
(iii) Hyperprolactinemia due to other causes (e.g. medical treatment, hypothalamic 
disease, other pituitary disease, pregnancy, lactation). 
 
4.4 Questionnaire 
The first draft of the questionnaire was developed by identifying areas of interest and after 
screening and research on potential standardised questionnaires. Additionally, we inserted 
general questions as published previously (62). 
 
The questionnaire encompassed the following parts (see attached document in the 
appendices):  
- Socioeconomic and baseline characteristics including sex, age, height and weight, 
occupational and family status, alcohol and tobacco consumption. 
- Medical specific history including questions regarding the diagnosis of prolactinoma 
(date, prolactin value, size of adenoma, visual field evaluation) and medical (type, 
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dose and duration) or surgical treatment and radiation. All the symptoms as well as 
possible side effects of the medical treatment were evaluated. 
- Gender specific questions including menstruation of female, number of children, 
medical and clinical history (apart from the prolactinoma), life-time comorbidities and 
family medical history. 
 
The first version of the questionnaire was distributed to a) a group of 5 experts at the Max-
Planck-Instiute, b) a small group of patients of the Endocrine Outpatient Unit of the Max 
Planck Institute of Psychiatry for improvements and revision. 
The final questionnaire was evaluated by the department of epidemiological psychology of 
the Max Planck Institute of Psychiatry and sent to the patients in May 2009. The response rate 
was about 30%. A database was created with Microsoft Access (Windows 2000), where all 
data were transferred for statistical analyses. 
 
4.5 DNA preparation, SNP selection and genotyping of the MDR1 transporter (ABCB1 gene) 
Forty millilitres of EDTA blood was drawn from each patient and DNA was extracted from 
fresh blood using the Puregene whole-blood DNA extraction kit (Gentra Systems, 
Minneapolis, MN, USA). Alternatively, for the patients that did not attend our Outpatient Unit 
at study point, Oragene®•DNA Self-Collection Kit (OG-500-tube format and OG-250-disc 
format) was sent to their home address and they were asked to return them with saliva 
samples in prepaid envelopes. Saliva samples were collected according to the manufacturer’s 
instructions that were enclosed in the German language. A 500 μL aliquot of an 
Oragene•DNA saliva sample was used for the DNA extraction according to the 
manufacturer’s instructions. Genotyping was performed with a LightCycler® 480 Genotyping 
Master (detailed genotyping procedure presented in appendices). Four ABCB1 SNPs were 
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genotyped (further details are given in Table 3). SNPs were selected from dbSNP 
(http://www.ncbi.nlm.nih.gov:80/) according to previous published data that revealed altered 
expression and function of the P-gp. None of the SNPs showed a significant deviation from 
the Hardy-Weinberg equilibrium and all genotypes could be determined (call rate 100%). 
 






Map_Pos Alleles HWE MAF Call 
rate 
ABCB1        
rs1045642 7 Exon 26 87138645 C/T 0,65 0,44 1,00 
rs2032582 7 Exon 21 87160618 G/T 1,00 0,47 1,00 
rs2032583 7 Intron 21 87160561 C/T 0,68 0,16 1,00 
rs2235015 7 Intron 4 87199564 G/T 0,49 0,20 1,00 
HWE: P-values of the Hardy-Weinberg equilibrium test; MAF: minor allele frequency 
Chromosomal positions are given according to the February 2009 (hg19) human reference sequence database of 
the International Human Genome Sequencing Consortium. 
 
4.6 Statistical analysis 
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS 
Version 16) for Windows. 
In the frame of the formulated hypothesis of the side effects and symptoms of treatment with 
cabergoline, percentages and frequencies of these symptoms under hormonal treatment were 
calculated. We also retrieved data from the disease and personally history and also medical 
procedures and we calculated means and standard deviations were calculated (SD). 
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The differences in continuous and categorical variables between 2-groups were analysed by 
the unpaired t-test (two-tailed) and Chi-square. A two-tailed p-value of 0,05 was considered 
statistically significant with a 95% confidence interval (CI) after corrections for multiple tests 
were performed. Differences that were considered statistically significant are marked in bold. 
Empirical instead of asymptotic p-values are reported: these have been calculated with a 
permutation-based method using 100000 permutations. SNPs were tested for 3 models of 
inheritance: allelic, carrier and heterozygote vs. homozygote. To correct for multiple testing, 
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5. RESULTS 
5.1 Description of the prolactinoma patient group 
The clinical study included a total of 92 patients consisting of 23 men and 69 women. The 
mean age of our group at the time of the study was 49,2 ± 13,8 years, whereas the mean Body 
Mass Index (BMI) was 25,6 ± 6,9 kg/m². Thirty six of the women that were asked had at least 
one child and 25,8% were already at the menopause (mean age 46 years). Higher was the 
percent of men having children (81%). Twenty six women reported of any irregular menstrual 
cycle since menarche, which occurred at a mean age of 13,5 years. 
Regarding their occupational status, 58,8% of the patients were employed at study point, 
whereas 22,4% reported being pensioned and 12,9% to be housewives. About half of the 
participants had rare or no alcohol consumption and also had never smoked. 68,2% were 
married and 22,4% single. 
Further demographic characteristics are presented in Table 4. Results of variables are 
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Table 4: Basic socio-demographic characteristics of 92 prolactinoma patients 
  Mean SD 
Age 49,2 13,8 
BMI 25,6 6,9 
Age of menarchy (female patients) 13,5 1,24 
Age of menopause (female patients) 46 8 
 N % 
Sex  
- men 23 25 
- women 69 75 
Work status  
- employed 50 58,8 
- unemployed 2 2,4 
- retired 19 22,4 
- housewife 11 12,9 
- other 3 3,5 
School years 3,4 11,4 
Legal status  
- single 19 22,4 
- married 58 68,2 
- divorced/widowed 8 9,4 
Smoking  
- no 48 56,5 
- yes 24 28,2 
- past 13 15,3 
Alcohol  
- daily 10 12 
- occasionally 10 12 
- rarely 16 19,3 
- extreme rarely/never 47 56,6 
Any irregular menstrual cycles 26 45,6 
Women in menopause 16 25,8 
Women with children 36 57,1 
Men with children 17 81 
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5.2 Lifetime comorbidities of prolactinoma patients 
Twenty four point four percent (24,4%) had the diagnosis of pituitary insufficiency, at least of 
one axis, that was not surprisingly, strongly correlated with the macroprolactinomas 
(p<0,001). The most affected axis was the gonadotropic axis with 17%, followed by the 
corticotropic (14,9%), the somatotropic (8,1%) and the thyreotropic axis (8%). Twenty one 
point two percent (21,2%) presented with hypertension, 12,9% had positive medical history of 
pulmonary disease, whereas the diagnosis of cancer and diabetes mellitus was lower at 4,7% 
each. Arrhythmia was present in up to 9,3% of our group. Five point four (5,4%) of patients 
had a positive medical family history for endocrine diseases (mostly thyroid abnormalities) 
and 30,4% for psychiatric diseases, including a wide range of psychiatric conditions, such as 
depression, psychosis, bipolar disorder, attempted suicide or schizophrenia. 
 
Table 5: Lifetime comorbidities of 92 prolactinoma patients 
 N % 
Pituitary insufficiency 22 24,4 
- corticotropic 13 14,9 
- thyreotropic 7 8 
- gonadotropic 15 17 
- somatotropic 7 8,1 
Hypertension 18 21,2 
Pulmonary disease 11 12,9 
Arrhythmia 8 9,3 
Diabetes mellitus 4 4,7 
Cancer 4 4,7 
Cerebrovascular disease 3 3,5 
Coronary disease 1 1,2 
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5.3 Disease and treatment history of prolactinoma patients 
The initial diagnosis was equal to micro- (51,1%, female-to-male ratio 8:1) and 
macroprolactinomas (48,9%, female-to-male ratio 1,5:1). The mean age at diagnosis was 38 ± 
13,8 years, whereas the study was conducted, on average, 11,3 ± 7,1 years after the first 
diagnosis of the tumour. The median serum prolactin concentration at baseline was 214,5 
ng/ml (range: 25-14900 ng/ml, median value for microprolactinomas 98 ng/ml, median value 
for macroprolactinomas 643 ng/ml). Data on precise tumour size at diagnosis were available 
only for the half of the adenomas, with a maximal diameter ranging from 2 to 60 mm. Sixteen 
patients had visual field disturbances at the time of diagnosis. Thirteen patients had undergone 
surgery (11 transsphenoidal, 2 transcranial) and two of the patients that had been operated, 
had undergone additional radiotherapy. Regarding the medical treatment, in 79 cases 
cabergoline was used (mean maximum dose 1 mg/week, range 0,25-7 mg), but 55 patients 
were treated with at least two different dopamine agonists. At study point, 49 patients were 
under treatment with cabergoline, six with bromocriptine and two with quinagolide and 62 
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Table 6: Disease diagnosis and treatment characteristics of 92 prolactinoma patients 
 N % 
Primary prolactinoma type   
- microprolactinoma 47 51,1 
- macroprolactinoma 45 48,9 
Visual field at diagnosis   
- influenced 16 17,6 
- not influenced 56 61,5 
- unknown 19 20,9 
Surgery 13 14,8 
Radiotherapy 2 2,3 
Medical treatment   
- Bromocriptine 31 34 
- Lisuride 3 3 
- Cabergoline 79 86 
- Quinagolide 17 18 
 
5.4 Comparison of basic socio-demographic characteristics, lifetime comorbidities and 
disease characteristics of prolactinoma patients to patients with non-functioning pituitary 
adenomas (NFPA) 
To compare the basic socio-demographic characteristics, the lifetime comorbidities and the 
disease characteristics of our patients, 60 patients with non-functioning pituitary adenoma as a 
clinical control group were recruited at the Endocrine Outpatient Unit of the Max Planck 
Institute of Psychiatry and the Department of Internal Medicine, Ludwig-Maximilian-
University of Munich in equal parts. The NFPA group included significantly older (mean age 
60,2 ± 10,6 years, p < 0,001) and more overweight patients (mean BMI 28,5 ± 5,1 kg/m², p = 
0,006). In the NFPA group, men were mainly affected (65%, p < 0,001) and the group 
included mostly macroadenomas up to 81,7%. The NFPA tended to be diagnosed later, at a 
mean age of 47,1 years. The study was conducted approximately 13 years after the diagnosis 
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of the NFPA, not significantly different from the time of diagnosis of prolactinomas. 
Regarding the treatment followed, the NFPA patients underwent significantly more surgery 
(96,3%) and radiotherapy (28,3%) compared to the prolactinoma patients (p < 0,001). 
 
Table 7: Baseline and disease characteristics - comparison of 92 prolactinoma patients to the 
60 patients of NFPA group 
 Prolactinomas NFPA p-value 
 Mean SD Mean SD  
Age 49,2 13,8 60,2 10,6 < 0,001 
BMI 25,6 6,9 28,5 5,1 0,006 
Age at diagnosis 38 13,8 47,1 10,5 0,002 
Years after diagnosis 11,3 7,1 12,6 7,8 ns 
  
 N % N %  
Sex  
- men 23 25 39 65 
- women 69 75 21 35 
< 0,001 
Type of adenoma  
- macroadenoma 45 48,9 49 81,7 
- microadenoma 47 51,1 4 6,7 
< 0,001 
Surgery 13 14,8 52 96,3 < 0,001 
Radiotherapy 2 2,3 2 28,3 < 0,001 
 
In terms of lifetime comorbidities, patients with NFPA suffered hypertension significantly 
more often (p=0,002). Regarding pituitary insufficiency of all axes, patients with 
prolactinomas had less frequent pituitary deficits, significance that remained statistically 
significant for each pituitary axis (p<0,001). Regarding the other lifetime comorbidities, no 
statistically significant differences were detected. 
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Figure 9: Lifetime comorbidities of the prolactinoma patients in comparison to the NFPA group (by 
percentage). 
 
* Statistically significant differences between prolactinoma and NFPA patients. 
 
5.5 Side effects of cabergoline in the patient group of prolactinomas treated with cabergoline  
Of the 79 patients with prolactinomas treated with cabergoline, the following side effects 
prevalent under treatment were more prominent: fatigue (n=35), headaches (n=26), depressed 
mood (n=26), sleep disorders (n=26), dizziness (n=22) and weight loss (n=16). 18 patients 
reported of decreased and 16 of increased libido. 17 patients had signs of paresthesia equal to 
aggressiveness and 19 patients reported of anxiety. 
We evaluated all the symptoms in terms of presence and change (enhancement vs. reduction 
or consistency). The patients reported primarily of enhancement of fatigue and increased 
libido, and secondarily about enhancement of depressed mood. Interestingly, the percentage 
of those patients who reported weight loss under treatment was higher than those who 
reported weight gain. In terms of all disorders apart from binge eating, we found statistically 
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All the symptoms and their frequencies observed in terms of presence and change under 
treatment with cabergoline are presented in Table 8. 
 
Table 8: Symptoms and side effects under treatment with cabergoline in the patient group of 
79 prolactinoma patients treated with cabergoline 
 









 N % (*) N % (*) N % (*) p-value§
Fatigue 35 44,3 16 20,3 50 63,3 <0,001 
Headaches 26 32,9 10 12,7 55 69,6 0,001 
Sleep disorders 26 32,9 11 13,9 53 67,1 <0,001 
Dizziness  22 27,8 7 8,9 57 72,2 <0,001 
Weight loss 16 20,3 13 16,5 50 63,3 <0,001 
Weight gain 13 16,5 10 12,7 51 64,6 <0,001 
Decreased libido 18 22,8 6 7,6 59 74,7 <0,001 
Increased libido 16 20,3 16 20,3 46 58,2 <0,001 
Depressed mood 26 32,9 12 15,2 54 68,4 <0,001 
Aggressiveness 17 21,5 7 8,9 59 74,7 <0,001 
Anxiety 19 24,1 7 8,9 57 72,2 <0,001 
Visual hallucinations 2 2,5 1 1,3 64 81 0,031 
Gambling 1 1,3 1 1,3 64 81 0,015 
Compulsive shopping 5 6,3 2 2,5 63 79,7 0,005 
Binge eating 5 6,3 1 1,3 64 81 0,077 
Trichotillomania 3 3,8 0 0 65 82,3 NA 
(*) Percentage of the group of patients that answered the question 
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5.6 Association analysis among the seven most common neuropsychiatric side effects of 
cabergoline and ABCB1 polymorphisms in prolactinoma patients treated with cabergoline 
As cabergoline was the only dopamine agonist tested to be a substrate of P-gp, we examined 
the effects of the ABCB1 SNPs on self reported side effects under treatment with cabergoline 
(presence and enhancement of symptom). We selected the most common neuropsychiatric 
side effects according to their frequencies under cabergoline (fatigue, headaches, sleep 
disorders, dizziness, increased libido, depressed mood and aggressiveness) and evaluated 
them with permutation analysis. In the carrier model, the carrier of a specific nucleotide was 
compared with the non-carrier. In the allelic model, each nucleotide was evaluated to have a 
2-fold higher effect in the genotype whereas in the last model the heterozygous vs. 
homozygous genotype of each SNP was compared. 
Amongst all 4 SNPs, only SNP rs1045642 and rs2032582 seem to play in role in mainly three 
neuropsychiatric side effects, fatigue, sleep disorders and dizziness in the carrier and 
heterozygous genetic model. SNPs rs2032583 and rs2235015 seem not to influence the side 
effects examined. 
The results of the carrier, allelic and heterozygote vs. homozygote models are presented in 
Tables 9-12. 
 
5.6.1 MDR1 transporter encoding gene ABCB1 SNPs rs1045642 and its association with side 
effects of cabergoline 
 
We found that the SNP rs1045642 had an influence on two side effects under cabergoline, 
which were fatigue and sleep disorders. For the other side effects e.g. headaches, increased 
libido, depressed mood, dizziness and aggressiveness, no association to their occurrence and 
SNP rs1045642 was found. 
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More specifically, significant effects were observed for the C-carriers of rs1045642 that 
presented less frequent fatigue under cabergoline in comparison to non-C-carriers 
(Pwycor=0,04, OR=0,23). 
Additionally, the heterozygous CT-individuals presented less frequent sleep disorders in 
comparison to homozygous CC or TT (Pwycor=0,02, OR=0,20). There was a marginal 
statistical significance revealing less frequent occurrence of enhancement of dizziness for the 
C-carriers both in the carrier model and in the allelic (Pnom=0,02, Pwycor=0,10, OR=0,15, 
Pnom= 0,08, Pwycor=0,19, OR=0,29). In the heterozygous and allelic model, CT individuals 
and C-carriers respectively tended to suffer less frequently from fatigue (Pnom=0,06, 
Pwycor=0,15, OR=0,48 and Pnom=0,07, Pwycor=0,22, OR=0,36). There was no further 
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Table 9: Association of SNP rs1045642 with side effects under cabergoline treatment 
(statistically significant effects are marked in bold) 
Genotypes CC=18, CT=33, TT=21, missing=7  
Presence of symptom Enhancement of symptom  
Pnom Pwycor OR Pnom Pwycor OR 
Headaches 
Carrier C 0,49 0,90 1,49 0,12 0,39 0,34 
Carrier T 0,73 0,99 0,78 1,00 1,00 0,99 
Het./Hom. 0,73 0,99 1,21 0,17 0,44 0,31 
Allelic 0,50 0,86 1,31 0,34 0,68 0,59 
Increased libido 
Carrier C 0,68 0,98 1,37 0,80 1,00 1,25 
Carrier T 1,00 1,00 1,05 0,91 1,00 1,15 
Het./Hom. 0,64 0,97 1,37 0,63 0,98 1,33 
Allelic 0,79 1,00 1,13 0,92 1,00 1,05 
Depressed mood 
Carrier C 0,51 0,91 0,68 0,79 1,00 1,20 
Carrier T 0,24 0,63 0,46 0,53 0,86 0,58 
Het./Hom. 0,10 0,30 0,39 0,78 0,99 0,78 
Allelic 0,80 1,00 1,11 0,57 0,93 1,33 
Sleep disorders 
Carrier C 0,07 0,20 0,36 0,36 0,80 0,51 
Carrier T 0,24 0,63 0,46 0,24 0,56 0,41 
Het./Hom. 0,01 0,02 0,20 0,05 0,16 0,21 
Allelic 0,65 0,96 0,83 0,96 1,00 1,03 
Fatigue 
Carrier C 0,02 0,04 0,23 0,57 0,96 0,68 
Carrier T 0,63 0,99 1,39 0,60 0,99 0,69 
Het./Hom. 0,07 0,22 0,36 0,30 0,70 0,52 
Allelic 0,06 0,15 0,48 0,90 1,00 0,96 
Dizziness  
Carrier C 0,43 0,86 0,61 0,02 0,10 0,15 
Carrier T 0,74 0,99 0,80 0,60 0,90 1,85 
Het./Hom. 0,31 0,71 0,54 0,10 0,30 0,17 
Allelic 0,75 0,99 0,87 0,08 0,19 0,29 
Aggressiveness      
Carrier C 0,77 1,00 1,18 0,22 0,64 3,33 
Carrier T 0,35 0,68 0,50 0,75 0,95 0,65 
Het./Hom. 0,56 0,94 0,69 0,51 0,92 1,74 
Allelic 0,46 0,82 1,39 0,30 0,65 1,81 
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5.6.2 MDR1 transporter encoding gene ABCB1 SNPs rs2032582 and its association with side 
effects of cabergoline 
 
We found that SNP rs2032582 had an influence only on enhancement of dizziness in favour 
of G-carriers. For the other side effects headaches, increased libido, depressed mood, sleep 
disorders, fatigue and aggressiveness, no significant association could be established. 
More specifically, in the analysis of SNP rs2032582 G-carriers seemed to be protected from 
enhancement of dizziness under cabergoline when compared with non-G-carriers 
(Pwycor=0,05, OR=0,14). There was a trend towards statistical significance in the allelic 
model in terms of enhancement of dizziness (Pnom=0,03, Pwycor=0,09, OR=0,28) but also in 
the heterozygous model in terms of enhancement of sleep disorders (Pnom=0,04, 
Pwycor=0,12, OR=0,20). The G-carriers and the GT-individuals tended to suffer less 
frequently from enhancement of headaches (Pnom=0,08, Pwycor=0,27, OR=0,27 and 
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Table 10: Association of SNP rs2032582 with side effects under cabergoline treatment 
(statistically significant effects are marked in bold) 
Genotypes GG=21, GT=34, TT=15, missing=9 
 Presence of symptom Enhancement of symptom 
 Pnom Pwycor OR Pnom Pwycor OR 
Headaches 
Carrier G 0,86 1,00 1,16 0,08 0,27 0,27 
Carrier T 0,39 0,79 0,60 0,37 0,68 0,49 
Het./Hom. 0,56 0,94 0,71 0,02 0,07 0,11 
Allelic 0,48 0,86 1,32 0,73 0,99 0,82 
Increased libido 
Carrier G 1,00 1,00 1,05 0,91 1,00 1,15 
Carrier T 0,66 0,99 0,73 0,81 1,00 0,81 
Het./Hom. 0,72 0,99 0,78 0,85 1,00 0,91 
Allelic 0,75 0,99 1,17 0,76 0,99 1,16 
Depressed mood 
Carrier G 1,00 1,00 1,03 0,92 1,00 1,12 
Carrier T 1,00 1,00 1,01 1,00 1,00 1,00 
Het./Hom. 1,00 1,00 1,02 0,94 1,00 1,08 
Allelic 1,00 1,00 1,01 0,96 1,00 1,04 
Sleep disorders 
Carrier G 0,60 0,93 0,68 0,23 0,53 0,41 
Carrier T 0,62 0,98 0,72 0,25 0,61 0,46 
Het./Hom. 0,33 0,74 0,58 0,04 0,12 0,20 
Allelic 1,00 1,00 1,01 1,00 1,00 1,01 
Fatigue 
Carrier G 0,52 0,91 0,63 0,23 0,49 0,43 
Carrier T 0,19 0,35 2,22 0,82 1,00 0,81 
Het./Hom. 0,50 0,91 1,42 0,21 0,55 0,44 
Allelic 0,20 0,45 0,61 0,62 0,95 0,80 
Dizziness  
Carrier G 1,00 1,00 1,06 0,01 0,05 0,14 
Carrier T 0,90 1,00 1,08 0,31 0,68 3,03 
Het./Hom. 0,87 1,00 1,11 0,35 0,66 0,38 
Allelic 0,98 1,00 0,99 0,03 0,09 0,28 
Aggressiveness 
Carrier G 0,81 0,99 0,79 0,66 1,00 1,75 
Carrier T 0,99 1,00 0,95 0,93 1,00 1,08 
Het./Hom. 0,77 1,00 0,81 0,64 0,98 1,49 
Allelic 0,91 1,00 0,94 0,86 1,00 1,15 
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5.6.3 MDR1 transporter encoding gene ABCB1 SNPs rs2032583 and its association with side 
effects of cabergoline 
 
For SNP rs2032583, our study showed no statistically significant influence to the examined 
side effects. There were, however, the following marginal effects to be seen: 
There was a trend towards statistical significance showing that both C-carriers (in the carrier 
and allelic model) and CT-individuals tended to suffer more frequently from headaches under 
the treatment with cabergoline (Pnom=0,05, Pwycor=0,14, OR=3,23, Pnom=0,04, 
Pwycor=0,14, OR=3,26, Pnom=0,06, Pwycor=0,20, OR=2,59, Table 11). There was no 
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Table 11: Association of SNP rs2032583 with side effects under cabergoline treatment 
(statistically significant effects are marked in bold) 
Genotypes CC=1, CT=22, TT=49, missing=7 
Presence of symptom Enhancement of symptom  
Pnom Pwycor OR Pnom Pwycor OR 
Headaches 
Carrier C 0,05 0,14 3,23 0,64 0,99 0,60 
Carrier T 1,00 1,00 NA 1,00 1,00 NA 
Het./Hom. 0,04 0,14 3,26 0,60 0,95 0,61 
Allelic 0,06 0,20 2,59 0,67 0,96 0,66 
Increased libido 
Carrier C 0,26 0,70 2,08 0,37 0,83 1,89 
Carrier T 1,00 1,00 NA 1,00 1,00 NA 
Het./Hom. 0,27 0,67 2,06 0,36 0,77 1,88 
Allelic 0,28 0,65 1,77 0,40 0,76 1,64 
Depressed mood 
Carrier C 0,57 0,96 0,70 0,52 0,96 0,53 
Carrier T 1,00 1,00 NA 1,00 1,00 NA 
Het./Hom. 0,57 0,95 0,71 0,53 0,91 0,53 
Allelic 0,60 0,94 0,75 0,53 0,89 0,58 
Sleep disorders 
Carrier C 0,57 0,96 0,70 0,25 0,60 2,17 
Carrier T 1,00 1,00 NA 1,00 1,00 NA 
Het./Hom. 0,57 0,95 0,71 0,26 0,63 2,18 
Allelic 0,60 0,95 0,75 0,28 0,65 1,83 
Fatigue 
Carrier C 0,87 1,00 0,86 0,81 1,00 0,81 
Carrier T 1,00 1,00 NA 1,00 1,00 NA 
Het./Hom. 0,86 1,00 0,86 0,82 1,00 0,81 
Allelic 0,88 1,00 0,89 0,78 0,99 0,84 
Dizziness  
Carrier C 0,32 0,75 1,85 0,35 0,72 0,33 
Carrier T 1,00 1,00 NA 1,00 1,00 NA 
Het./Hom. 0,32 0,74 1,87 0,31 0,73 0,33 
Allelic 0,34 0,71 1,65 0,40 0,73 0,38 
Aggressiveness 
Carrier C 0,59 0,96 0,69 0,96 1,00 0,93 
Carrier T 1,00 1,00 NA 1,00 1,00 NA 
Het./Hom. 0,60 0,96 0,69 0,93 1,00 0,93 
Allelic 0,61 0,95 0,73 0,98 1,00 0,94 
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5.6.4 MDR1 transporter encoding gene ABCB1 SNPs rs2235015 and its association with side 
effects of cabergoline 
 
For the SNP rs2235015, no statistically significant association with the examined side effects 
apart from some marginal effects was found. 
There was a trend towards statistical significance showing that T-carriers and heterozygote 
individuals GT tended to suffer more frequently from headaches under treatment with 
cabergoline, a difference that turned out to be of no significance when corrected for multiple 
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Table 12: Association of SNP rs2235015 with side effects under cabergoline treatment 
(statistically significant effects are marked in bold) 
Genotypes GG=46, GT=22, TT=4, missing=7 
 Presence of symptom Enhancement of symptom 
 Pnom Pwycor OR Pnom Pwycor OR 
Headaches  
Carrier G 0,94 1,00 1,43 0,24 0,76 0,33 
Carrier T 0,04 0,09 3,23 0,91 1,00 0,89 
Het./Hom. 0,03 0,08 3,95 0,60 0,95 0,61 
Allelic 0,13 0,27 0,46 0,87 1,00 0,88 
Increased libido 
Carrier G 0,78 0,99 0,60 0,82 1,00 0,65 
Carrier T 1,00 1,00 1,01 0,92 1,00 0,90 
Het./Hom. 0,88 1,00 0,89 0,80 1,00 0,80 
Allelic 0,90 1,00 0,92 1,00 1,00 1,00 
Depressed mood 
Carrier G 1,00 1,00 1,29 0,72 0,94 0,38 
Carrier T 0,25 0,65 0,50 0,33 0,66 0,41 
Het./Hom. 0,25 0,63 0,49 0,17 0,42 0,22 
Allelic 0,31 0,62 1,72 0,61 0,92 1,51 
Sleep disorders 
Carrier G 1,00 1,00 1,29 0,79 0,97 0,44 
Carrier T 0,25 0,65 0,50 1,00 1,00 1,01 
Het./Hom. 0,25 0,63 0,49 0,79 1,00 0,80 
Allelic 0,31 0,62 1,72 0,83 1,00 0,86 
Fatigue 
Carrier G 0,60 0,93 2,33 0,77 0,99 0,65 
Carrier T 0,28 0,56 0,55 0,47 0,83 0,60 
Het./Hom. 0,45 0,87 0,63 0,39 0,79 0,50 
Allelic 0,26 0,55 1,73 0,65 0,96 1,34 
Dizziness  
Carrier G 1,00 1,00 1,95 0,19 0,62 0,25 
Carrier T 0,70 0,99 0,28 0,23 0,51 0,26 
Het./Hom. 0,69 0,98 1,32 0,05 0,21 0,00 
Allelic 0,75 0,99 0,85 0,61 0,92 1,65 
Aggressiveness 
Carrier G 0,78 1,00 0,73 0,17 0,60 0,24 
Carrier T 0,33 0,72 1,04 0,77 0,97 0,71 
Het./Hom. 0,25 0,63 0,43 0,36 0,80 0,35 
Allelic 0,47 0,83 1,53 0,86 1,00 0,91 
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6. DISCUSSION 
6.1 Main and secondary findings 
In this study, we investigated potential genetic predictors of neuropsychiatric side effects of 
cabergoline in patients with prolactinomas under DA therapy. 
 
We found that: 
(I) The comparison of the prolactinoma patients with the clinical control group of NFPA 
patients revealed a different profile of baseline and disease characteristics and also an 
individual spectrum of lifetime comorbidities possibly caused by long-term 
hyperprolactinemia or treatment with dopamine agonists. 
(II) In particular, the prolactinoma group showed a high prevalence of neuropsychiatric 
symptoms under treatment with cabergoline, such as depressed mood, fatigue, sleep 
disorders, aggressiveness and anxiety. 
(III) In regard to our main study hypothesis, we observed that prolactinoma patients with a 
specific genotypic profile e.g. C-carriers and heterozygous CT-individuals of SNP 
rs1045642 and G-carriers of SNP rs2032582 presented less frequently fatigue, sleep 
disorders and also seemed to be protected from enhancement of dizziness respectively 
under medical treatment with cabergoline. However, SNPs rs2032583 and rs2235015 do 
not seem to influence the occurrence of the examined side effects under cabergoline. 
Additionally, for the majority of the neuropsychiatric side effects of cabergoline in 
prolactinoma patients tested (headaches, increased libido, depressed mood and 
aggressiveness), the MDR1 transporter encoding ABCB1 gene does not seem to play 
any predictive role. 
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Ad (I): The comparison of our prolactinoma patients with 60 patients of a clinical control 
group of NFPA revealed that our patients were significantly younger. Greenman et al. (63) 
report an average age of diagnosis between 50 and 55 years for the NFPA, whereas in our 
group the tumour was earlier diagnosed (mean age at diagnosis 47,1 years). This slight 
difference could be attributed to the informed group of patients and/or doctors prompting 
earlier medical consultation when noticing some signs and symptoms that usually tend to be 
ignored. The patients of the NFPA group included significantly more overweight patients in 
comparison to the prolactinoma patients but it should be considered that our results are not 
adjusted for age and gender. 
Concurrent to the described sex preference of prolactinomas in the female, our prolactinoma 
group included more female patients than the NFPA group in a female-to-male ratio 3:1. 
Gender differences in tumour size are supposed to exist in hyperprolactinemia since 
microprolactinomas are more commonly found in women and macroprolactinomas in men, 
results that were also to be seen in our study. Possible reasons for this could be either a delay 
in diagnosis in men or a true gender difference in tumour pathogenesis (13); however, there is 
still no exhaustive explanation about this phenomenon. It could be speculated that the 
increased prevalence of prolactinomas in women could be due to the observation that the 
symptoms in women are more evident (amenorrhea, galactorrhea) and lead earlier to the 
diagnosis, whereas the features of hypogonadism (impotence and decreased libido) are less 
readily evident, not so specific and seem to be ignored. The pathogenesis of the tumour seems 
also to be under a gender control, as indicated by autopsy studies (64). However, studies 
comparing the clinical and pathological correlates of growth of these tumours in both sexes 
are lacking. There is only one study of Delgrange et al. implicating a different pathogenesis 
and revealing a greater growth potential of macroprolactinomas in men than in women as well 
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as a male predominance of aggressive forms of the disease (e.g. giant, invasive, and malignant 
prolactinomas) (65).  
We report additionally but not surprisingly, results in consistency with the available literature 
(63) showing increased prevalence of macroadenomas in the NFPA group. 
Due to a lack in sufficient medical treatment of NFPA, surgery remains the main primary 
therapeutical procedure, whereas in patients with prolactinomas a therapy with dopamine 
agonist agents is in the vast majority of the cases indicated. The prolactinomas seemed to be 
diagnosed at a younger age than the NFPA and the reasons seem to be not only the earlier de 
novo onset of the tumour (63, 66), but also the earlier diagnosis due to the evidence of mostly 
prominent symptoms such as amenorrhea and galactorrhea, whereas NFPA present often 
without any symptomatology or with unspecific signs of pituitary deficits and seem to be 
attributed to other causes both from the physicians and patients. 
Regarding the lifetime comorbidities, our patients with prolactinomas reported less frequent 
hypertension, reflecting most probably their younger age. In terms of pituitary insufficiency, 
statistically more insufficiency of all axes is being reported in the NFPA group, representing 
the increased prevalence of macroadenomas and the surgical resection of the tumour mostly 
followed. We present a 45% prevalence of any axis of pituitary insufficiency in the NFPA 
group, primarily based on previous pituitary testing, but also on the patient’s knowledge of 
this abnormality. In previous studies, symptoms of hypopituitarism seem to be prevalent in 
roughly 40-52% of patients (63). However, formal testing of pituitary function always tends 
to reveal a higher incidence of pituitary hypofunction that can be up to 70% or more. 
 
In the prolactinoma group the gonadal axis was the most commonly affected, followed by the 
corticotropic. This discrepancy with the available literature data, that reports most frequent 
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insufficiency of the somatotropic axis (67) reflects most probably a reporting or diagnostic 
bias, since the somatotropic insufficiency often remains undiagnosed or even untreated and 
the patients are probably not aware of it. 
 
Ad (II): We present an increased prevalence of neuropsychiatric symptoms under treatment 
with cabergoline in our prolactinoma group. More specifically, fatigue was present in 44% of 
our patient group, significantly increasing in 20% of patients. About 33% of patients 
complained about headaches and more than one third of patients seemed to experience a 
depressed mood under treatment with cabergoline.  
Side effects associated with cabergoline administration are common but seem to be less 
frequent in comparison with bromocriptine at least in terms of nausea and vomiting (48). 
There are many studies examining the different side effects of cabergoline in patients with 
prolactinoma. However, to our knowledge, the existing studies do not compare the symptoms 
and signs in terms of changes under treatment with cabergoline and our study is the first in the 
literature with this approach up to now. 
Therefore, we addressed the presence of symptoms under cabergoline and we asked the 
patients to evaluate them in terms of change, enhancement or not (reduction and consistency). 
This seems to be important, because some signs such as headaches, fatigue or sleep disorders, 
when evaluated only under medical treatment, could be frequent in a false positive way 
because they could be correlated to the medication but also to the state of non-recurrent 
hyperprolactinemia, the presence of the pituitary mass and secondary pituitary insufficiency. 
Furthermore, we can assume that the presence of a symptom - when asked to be evaluated in 
terms of change under treatment - could be in all likelihood attributed to the treatment itself. 
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More specifically, fatigue seems to be the most common symptom under treatment with 
cabergoline, significantly increasing in 20% of patients. We observed a higher proportion of 
patients suffering from fatigue under treatment in comparison to the available literature where 
data in different studies vary from 13-18% (68). However, our data are rather consistent when 
evaluated in terms of enhancement of fatigue under treatment, taking into consideration that 
this percentage is the true attributed side effect to the medication. Additionally, Kars et al. 
evaluated fatigue with MFI-20 (Multidimensional Fatigue Inventory) and its five different 
dimensions: a) general fatigue, b) physical fatigue, c) reduced activity, d) reduced motivation 
and e) mental fatigue and revealed an impaired reduced fatigue profile in the first four traits, 
when compared to controls. Present use of dopamine agonist (about 60% cabergoline in this 
patient group) seemed to be a major determinant of reduced activity (c), contributing 
significantly to the onset of fatigue (69).  
Headaches remain one of the main complaints of patients with pituitary lesion of any origin 
with a frequency up to 40% (70, 71).  Approximately one third of our group reported of 
headaches under cabergoline, with 10% of them complaining of enhancement of the 
symptom. Webster et al. report of consistent results with approximately 30% of patients 
suffering from headaches under cabergoline (68). However, headaches also seem to be a 
common important problem before the initiation of treatment, as Colao et al. (72) states. The 
physician should keep in mind this important side effect, but should also exclude by 
persistence of the symptom, other serious causes such as tumour growth or pituitary apoplexy. 
Dizziness or vertigo, that occurs in up to 27,8% of our patient collective, appears to be one of 
the most important reasons of discontinuation of the therapy in consistency with the previous 
data, reporting of a prevalence of 25% under treatment with cabergoline (68). It seems though 
to be ameliorated when cabergoline is administered after the meal at night.  
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In terms of depressed mood, we observed a high proportion of patients (up to 33%) 
complaining of depressed mood, worsened in 15% under cabergoline. In experimental models 
(73) and case reports (74) though, cabergoline has been found to exert antidepressant effects 
but larger studies are needed to fully elucidate this observation. We demonstrated a rather 
high percentage of depressed mood in our patient collective compared with the available 
literature. Webster et al. (68), report of 3% of depression under cabergoline, whereas in the 
studies of Sabuncu et al. and Ono et al., no psychiatric side effects have been described (75, 
76). 
 
Our observation could reflect a possible selection bias due to the low response rate, leading to 
the conclusion that our patient collective included primarily patients of increased age and 
were more affected from the disease. However, it should also be also taken into consideration, 
that we did not conducted standardised personal interviews to diagnose depression, but asked 
the patients’ perception of their mood under treatment. A further limitation in the 
interpretation of our results is also the fact that our Endocrine Outpatient Unit is located in a 
psychiatric and neurologic clinic (Max Planck Institute of Psychiatry), with patients suffering 
more often from comorbid mood disorders and prolactinoma being referred to our department 
more frequently than the patients without these kinds of symptoms. 
 
In the available literature, quality of life seems to be impaired in female patients treated for 
microprolactinoma, especially due to increased anxiety and depression (69) but the link of this 
result is poorly defined. In this later study, the authors evaluated the depression and quality of 
life in 55 female patients with microprolactinoma, where the current use of dopamine agonist 
or the present prolactin levels were not evaluated in terms of depression. Several points could 
provide insight to understand the relationship of prolactinoma and emotions, including the 
central effects of hyperprolactinemia and the patient’s knowledge of having a “brain tumour”. 
 - 58 -
Prolactin has been found to act on the central nervous system and may be associated with 
irreversible changes in neural function, that could probably be translated to alterations in 
behaviour,  emotions,  feelings and  personality (77). A number of studies have documented 
an altered psychological profile and emotional difficulties in patients with prolactinomas, 
mainly characterised by increased anxiety, depression and impaired quality of life (69, 78), 
changes that occasionally persist even after remission of the hyperprolactinemia (77). The 
clinician should keep in mind this impaired psychological status of this group of patients 
when treating them.  
 
Ad (III): In general, our study does not demonstrate any significant correlation of the four 
examined SNPs of the ABCB1 gene rs1045642, rs2032582, rs2032583 and rs2235015 with 
the vast majority (headaches, increased libido, depressed mood and aggressiveness) of the 
most common side effects of cabergoline. 
 
However, we have to point out some interesting results: 
We demonstrated that the C-carriers of SNP rs1045642 were rather protected compared to the 
non-C-carriers, in terms of suffering from sleep disorders and fatigue under cabergoline. 
Additionally, heterozygous CT-individuals of SNP rs1045642 presented less frequent sleep 
disorders than homozygous CC and CT. Regarding enhancement of dizziness under 
cabergoline, non-G-carriers of SNP rs2032582 seemed to experience a 7-fold higher risk to 
suffer from it than the G-carriers. In terms of further central side effects such as headaches, 
increased libido, depressed mood or aggressiveness our study failed to demonstrate any 
statistical significance. 
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As has been well established from different studies, the P-pg activity depends on the 
expression of P-gp and also its functionality. Both parameters seem to interfere and 
secondarily influence intracerebral concentrations of the substrates of P-gp. In terms of 
expression, MDR1 has been found to be overexpressed in cases of insensitivity of tumour 
cells toward chemotherapy due to amplifications or other mechanisms (79). Functionality 
reflects the effectiveness of the MDR1, leading to abnormal increased accumulation and 
potential adverse events.  
 
To our knowledge, there are few studies addressing the influence of ABCB1 polymorphisms 
and all of them refer to antidepressants that are substrates of this molecule. In this case, a low 
ABCB1 activity is desired, in order to achieve higher intracerebral concentrations and 
increase the remission rate. In the case of cabergoline and dopamine agonist in general 
though, where the target of treatment is outside the BBB, low intracerebral concentrations do 
not influence therapy response, protecting at the same time from the occurrence of central side 
effects. 
As indicated from many different studies, the interindividual and genotypic variability of the 
P-gp in the blood brain barrier could influence secondarily the degree of expression and the 
functionality of the MDR-1 gene product and therefore directly affect the therapeutic 
effectiveness of such agents that are substrates of P-gp, with the results reported remaining 
inconsistent. 
Gex-Fabry et al. (80) and Mihaljevic Peles et al. (81) implicated that rs203582 and rs1045642 
did not influence the response to paroxetine and both Peters et al. (82) and Laika et al. (83) 
showed that none of these genetic polymorphisms in the pharmacokinetic genes examined 
were significantly associated with our response or tolerance. 
 
 - 60 -
However, both Hoffmeyer et al. and Kato et al., reported that the C variant of SNP rs1045642 
and G variant of SNP rs2032582 were associated with higher P-gp expression and function 
(60, 84) and therefore poor response to antidepressants, leading to a more severe depressive 
symptomatology. Conflicting results have also been reported (85), showing an increased 
remission of depression in the G-carriers SNP rs2032582, presenting with higher CSF 
concentrations. 
 
These latest results are in accordance with our findings that report both less frequent 
occurrence of side effects and enhancement of them under cabergoline in the individuals 
having the “protective” genotype reflecting the lower intracerebral concentrations of the 
medication. 
Nevertheless, our study was focused on the evaluation of some specific genetic predictors of 
ABCB1. We suppose there are further transporting molecules and genetic pathways that 
influence the metabolism and action of cabergoline in the brain circulation and further studies 
need to be conducted to elucidate these mechanisms. 
At any case, the study points to the genetically determined investigation of side effects that 
could have promising results in terms of personalised medicine and could predict, before 
initiation of treatment, how the individual’s genetics affects his or her side effects. This could 
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Apart from the three mentioned main findings, we can also point out the following 
observations: 
(i) Treatment with dopamine agonists and weight loss 
The treatment with cabergoline seems to cause a weight loss in up to 20% of our patients.  
Significant interactions seem to exist between hyperprolactinemia and weight control. 
Hyperprolactinemia in humans is associated with a high prevalence of obesity and insulin 
resistance (86) and patients with prolactinomas, especially macroprolactinomas tend to have 
increased body weight in comparison to healthy individuals (87). Human and animal studies 
have also implicated that dopamine, as a neurotransmitter, modulates rewarding properties of 
food and plays a significant role in appetite regulation (36) and more recently, different 
polymorphisms of D2 receptor have been linked to obesity (88), suggesting that individuals 
may overeat to compensate for hypofunctioning dopaminergic signalling (89, 90). 
Normalisation of prolactin levels, after treatment with dopamine agonists, has been associated 
with weight loss (91-93) but the nature of this link is poorly defined. In most of the available 
studies a significant weight loss after treatment with bromocriptine was observed (91, 92, 94). 
More specifically Doknic et al. (94) demonstrated significant weight loss implying that 
bromocriptine influences body weight by mechanisms in addition to reducing 
hyperprolactinemia. Adding some controversy, another study of 39 hyperprolactinemic 
patients treated with different dopamine agonists, failed to demonstrate such correlation (95). 
On the other hand, Greenman et al. (91) in a retrospective study of 42 patients with 
prolactinomas and 36 patients with clinically non-functioning macroadenomas, attributed 
weight loss not to the therapy with bromocriptine or its pharmacological side effects, but 
exclusively to the normalisation of prolactin levels. 
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Regarding cabergoline, there are only two studies available in the literature providing insight 
to the effect of this commonly used medication on body weight in prolactinoma patients. In 
the first study of Korner et al. (93), a weight loss effect attributable to cabergoline treatment 
was noted, whereas in another more recent case-control study of Serri et al. (86), no 
significant changes in body weight after treating prolactinoma patients with cabergoline 
occurred. 
 
The animal models are mostly lacking in available weight data, while the weight effect of 
dopamine agonists in patients with Parkinson’s disease is difficult to estimate due to 
confounding factors affecting this group (dysphagia, anorexia, gastrointestinal dysfunction 
etc.). 
 
In conclusion, the available data regarding this topic are rather controversial and do not prove 
causality. To clarify further the relationship between hyperprolactinemia, body weight and 
dopamine agonist therapy and more specifically the plausible pathophysiological mechanism 
responsible for this, further studies should be conducted. 
 
 (ii) Impulsive control disorders and dopaminergic signalling 
In our study we managed to show an increased libido under treatment with cabergoline in 
20% of patients, whereas small numbers of gambling (1 patient), compulsive shopping (5 
patients) and binge eating have been referred (5 patients). The increase of libido could have 
been anticipated to a certain extent, taken into consideration that hyperprolactinemia and 
prolactinomas cause hypogonadism and impaired sexual and reproductive function. The 
normalisation of prolactin levels leads to a restorement of libido and sexual function. To what 
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extent the increased libido remained in the normal range, or whether it tended to be a 
pathological hypersexuality, could not be clearly evaluated due to the lacking of a personal 
interview with the patients. However, the 20% enhancement of increased libido could be 
implicating a trend to an abnormal extent of this symptom. 
In patients with Parkinson's disease under treatment with dopamine agonists, increased 
prevalence of pathological behaviours characterised by compulsion and impulsivity have been 
described such as pathological gambling, hypersexuality, compulsive shopping and eating. All 
these disorders, known as impulsive control disorders may develop, according to the available 
literature, in up to 30% of people taking higher agonist doses (96) that tend to be 20-fold 
higher than the mean weekly dose used for prolactinomas and could also persist after the 
withdrawal of the medication. Additionally, in individuals with Restless Legs Syndrome on 
dopamine agonist therapy, it was suggested that impulse control disorders can occur over a 
wide range of dopamine agonist therapy types and dose exposures. 
To our knowledge, there are only 2 case reports in the literature reporting of hypersexuality 
and gambling in female and male patients, both being treated for a microprolactinoma with a 
dose of 0,25 mg and 1 mg weekly respectively (56, 57). In both cases, the symptoms were 
ceased after the withdrawal of cabergoline. 
At this point, we have to recall the dopaminergic basis of impulsivity. The chronic exposure 
to intermittent administration of substances such as dopamine agonists that increase 
dopaminergic levels, may also affect impulsive choice. A recent study demonstrated that DA 
use status was associated with a greater choice impulsivity in Parkinson’s patients as 
compared to PD controls (97). Dopamine neurotransmission, along the mesocorticolimbic 
pathway, is a potential modulator of risk behaviour. In cases of medical treatment with 
dopamine agonists, the direct upregulation of the dopaminergic tone could be a plausible 
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explanation but baseline differences or differences of response to DA should also be 
addressed. Furthermore, studies with administration of DA in healthy volunteers to evaluate 
the impulsive behaviour are scarce up to now and therefore only indicative conclusions based 
on the Parkinson’s patient’s population can be drawn. 
Taking into consideration the aforementioned observations, it remains of clinical importance 
in the daily practice that these possible complications do not escape doctors' attention 
remaining underdiagnosed. Such pathological behaviours can frequently lead to considerable 
marital or occupational conflicts or if severe, become a problem also from ethical and legal 
points of view. Cabergoline-induced pathological gambling and hypersexuality and in general 
ICDs are probably under-reported and physicians should consider screening for these in 
patients treated with dopamine agonists and establish a multidisciplinary approach. 
 
6.2 Strengths and limitations 
Of the 308 patients treated at the Endocrine Outpatient Clinic of the Max Planck Institute to 
whom a questionnaire was sent, 225 were female patients (73%) and the female-to-male ratio 
was approximately 2,7:1. Of the 92 patients who participated in our study (percentage of 
participation 30%) the ratio was similar at 3:1. In the initial group of 308 patients, 198 were 
diagnosed with microprolactinomas and 110 with macroprolactinomas, whereas in our study 
group we observed an equal prevalence of micro- and macroprolactinomas, reflecting 
probably the increased health concern of the latest group of patients. Therefore, we have to 
assume that in terms of tumour art, our group was not reflecting the initial group of patients 
treated in the Endocrine Outpatient Clinic; however, both types of adenomas were sufficiently 
represented. 
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As expected, few patients underwent a surgical approach, reflecting the high rate of remission 
under medical treatment. 86% of our patients received, in their disease history, cabergoline, 
which is, according to the latest guidelines of the Endocrine Society (34), the dopamine 
agonist of choice. As our group included subjects with a long disease history from 
approximately diagnosis since the 1970s, other dopamine agonists such as bromocriptine, 
lisuride and quinagolide had been used. 
Our patients tended to be overweight at study point. As indicated from Colao (66), patients 
with hyperprolactinemia often present weight gain, tending also to have an altered body 
composition with increased fat mass and reduced lean mass, even when non-obese (98). We 
did not present data regarding weight at the time of diagnosis, which could probably reflect 
better the effect of hyperprolactinemia on weight gain. Due to the small sample size, we did 
not conduct further analysis evaluating the BMI of patients in terms of pituitary insufficiency 
(e.g. of somatotropic axis, knowing to be present with increased fat mass) or prolactin levels, 
implying that the increased BMI may also reflect insufficient substitution of the pituitary axes 
or even uncontrolled disease. 
 
The strength of our study is that it is the first to address the important topic of 
neuropsychiatric side effects of cabergoline in terms of different genetic predictors of 
ABCB1. The novelty finding of cabergoline, being a substrate of P-gp, presented in our study, 
will expand the current knowledge on DA-treatment. 
 
An important percentage of patients to whom the questionnaire was sent did not respond 
(70%). This may be due to the extended and specialised questions that were included 
regarding medical and disease history or due to their nature of the neuropsychiatric details 
that the patients may not have wanted to answer, leading to a decreased response rate, 
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(selection bias). Additionally, due to a relative low response rate we have to hypothesise that 
the patients that finally participated in our study were probably the older or more affected of 
the pituitary lesions of our initial group, who due to increased health concerns, dedicated their 
time to participate in our study.  
 
Another source of bias is additionally the “missing data” that occurs from a false response or 
misunderstanding of the questions (measurement bias). 
The data collected for the study was obtained mainly from the questionnaire and in the case of 
missing data or uncertainty, additional information was obtained by file review. Therefore, the 
results consisted partly from information which was based on the patient’s own perception. 
No personal interview was conducted. The reported trends e.g. for depressed mood or 
aggressiveness, reflected the patient’s impression for his symptoms were not validated or 
diagnosed from a specialised physician according to the ICD-10 (ICD-10: International 
Statistical Classification of Diseases and Related Health Problems 10th Revision). 
Furthermore, due to the small size of our sample we could not evaluate our results controlling 
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7. CONCLUSION 
This is the first study demonstrating that polymorphisms of the MDR1 (or P-gp) encoding 
ABCB1 gene could account for a different occurrence or enhancement of central side effects 
of the systematically administered cabergoline. As cabergoline was tested and found to be a 
substrate of MDR1, the individual’s genetic polymorphisms account for differences in 
function and expression of P-gp, controlling the intracerebral concentration of cabergoline. 
More specifically in regard to our main study hypothesis, we observed that prolactinoma 
patients with a specific genotypic profile e.g. C-carriers and heterozygous CT-individuals of 
SNP rs1045642 and G-carriers of SNP rs2032582, presented less fatigue, less frequent sleep 
disorders and also seemed to be protected from enhancement of dizziness respectively under 
medical treatment with cabergoline. SNPs rs2032583 and rs2235015 in our study and for the 
side effects tested do not seem to influence their occurrence under cabergoline. For the 
majority of the neuropsychiatric side effects of cabergoline in prolactinoma patients tested 
(headaches, increased libido, depressed mood and aggressiveness), the MDR1 transporter 
encoding ABCB1 gene does not seem to play any predictive role. 
Secondary, the comparison of the prolactinoma patients with the clinical control group of 
NFPA patients, revealed a different profile of baseline and disease characteristics and also an 
individual spectrum of lifetime comorbidities possibly caused by long-term 
hyperprolactinemia or dopaminagonist therapy. 
In terms of prevalence of neuropsychiatric symptoms under cabergoline, our study revealed a 
significantly higher prevalence of them, such as depressed mood, aggressiveness, anxiety, 
fatigue and sleep disorders. 
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8. ABSTRACT/SUMMARY 
Background: Prolactinomas are the most frequent pituitary adenomas. The treatment with 
cabergoline, the most common dopamine agonist used, is associated with side effects such as 
nausea, vomiting, dizziness, headaches, movement disorders and fatigue. There is some 
additional evidence from case reports and small studies that some patients report 
neuropsychiatric side effects such as depression, gambling, hypersexuality and impulsive 
control disorders. 
Objective: In this cross-sectional study we sought to investigate the baseline clinical, 
demographic and disease characteristics of our patient group as well as life-time 
comorbidities. Additionally, side effects under treatment with cabergoline (prevalence and 
enhancement) and whether genetic variants of the ABCB1 gene (coding MDR1 or P-gp) 
could account for difference in the central neuropsychiatric side effects were investigated. 
Methods: Questionnaires evaluating medical history, therapy side effects and further 
demographic characteristics were sent to all prolactinoma patients currently treated at the Max 
Planck Institute of Psychiatry in Munich. Additionally, DNA extracted either from blood or 
saliva samples was genotyped for each patient. 
Results: The clinical study included a total of 92 patients (23 male and 69 female, macro-to-
microadenoma-ratio 1:1). The mean age of our group at the time of the study was 49,2 ± 13,8 
years. Of the 79 patients treated with cabergoline, the following side effects associated with 
treatment were more prominent: fatigue (n=35), headaches (n=26), depressed mood (n=26), 
sleep disorders (n=26), dizziness (n=22), aggressiveness (n=17), anxiety (n=19) and weight 
loss (n=16). 18 patients reported of decreased and 16 of increased libido. Significant effects 
were observed for the C-carriers and heterozygous CT-individuals of rs1045642 that 
presented less frequent fatigue and sleep disorders under cabergoline. In the analysis of SNP 
rs2032582, G-carriers seemed to be protected from enhancement of dizziness under 
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cabergoline. SNPs rs2235015 and rs2032583 were found to have no association with the 
examined symptoms. 
Conclusion: In our group we described an increased prevalence of symptoms such as fatigue 
and weight loss under cabergoline, as well as neuropsychiatric side effects such as depressed 
mood, aggressiveness and anxiety in comparison to the available data of the literature. We 
demonstrated that polymorphisms of SNPs rs1045642 and rs2032582 of the ABCB1 gene 
predispose for fatigue, sleep disorders and dizziness under cabergoline. This is the first study 
demonstrating that individual ABCB1 gene polymorphisms could account for a different 


















 - 70 -
9. ZUSAMENFASSUNG (SUMMARY) 
Hintergrund: Prolaktinome sind die häufigste Hypophysenadenome. Medikamentöse 
Therapie der ersten Wahl sind Dopaminagonisten wie das Ergotderivat Cabergolin. 
Fallberichte und kleinere Studien weisen darauf hin, dass es bei einigen  Patienten unter dieser 
Therapie zu neuropsychiatrischen Nebenwirkungen wie Spielsucht, Hypersexualität, 
übermäßigem Einkaufen, Essanfällen oder depressiven Verstimmungen kommt. Cabergolin 
ist ein Substrat des Transportermoleküls MDR1 (P-Glykoprotein) der Bluthirnschranke. 
MDR1 wird durch das ABCB1-Gen kodiert und kommt in der Allgemeinbevölkerung in 
verschiedenen Polymorphismen vor. Das  durch das ABCB1 Gen kodierte P-gp führt an den 
Blut-Hirn-Schranke dazu, dass seine Substrate zurück ins Blut transportiert werden und deren 
Konzentrationen im Gehirn niedrig bleibt. 
Objektive: Es handelt sich um eine nicht-interventionelle diagnostische Querschnittsstudie zur 
Untersuchung von Nebenwirkungen und genetischer Polymorphismen des ABCB1 Gens für 
Nebenwirkungen einer dopaminagonistischen Therapie mit Cabergolin bei Patienten mit 
Prolaktinomen. 
Methodik: 308 ambulante Patienten mit der Diagnose Prolaktinom, die in der 
Endokrinologischen Ambulanz des Max-Planck-Instituts für Psychiatry behandelt werden, 
wurden angesprochen und 92 haben an der Studie teilgenommen. Entsprechende Fragebögen 
wurden von den Patienten ausgefüllt und genetische Analysen mittels Extraktion von DNA 
von Blut- oder Speichelproben wurde durchgeführt. 
Ergebnisse: 92 Prolaktinompatienten wurden rekrutiert (23 Männer, 69 Frauen, Mikro-zu-
Makroadenom Verhältnis 1:1). Das Durchschnittsalter war 49,2 ± 13,8 Jahre. 79 Patienten 
wurden mit Cabergolin behandelt. In der Gruppe der Patienten, die mit Cabergolin behandelt 
sind, wurden vorwiegend die folgenden Nebenwirkungen beobachtet: Müdigkeit (n=35), 
Kopfschmerzen (n=26), depressive Verstimmung (n=26), Schlafstörungen (n=26), Schwindel 
(n=22), Aggressivität (n=17), Angst (n=19) und Gewichtsabnahme (n=16). C-carriers und CT 
 - 71 -
Heterozygoten des SNPs rs1045642 sowie G-carriers des SNPs rs2032582 wiesen weniger 
Müdigkeit, Schlafstörungen und Verstärkung von Schwindel während der Therapie mit 
Cabergolin auf. Keine signifikanten Unterschiede für SNPs rs2235015 und rs2032583 
konnten nachgewiesen werden. 
Zusammenfassung: Wir schließen daraus, dass die Prolaktinompatienten eine erhöhte Zahl 
von neuropsychiatrischen Nebenwirkungen nachweisen und die SNPs rs1045642 and SNP 
rs2032582 des ABCB1-Gens eine protektive Rolle im Hiblick auf die Entwicklung von 
Schlafstörungen, Müdigkeit und Verstärkung von Schwindel spielen. Zukünftig sind klinische 
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Name : _____________________________________ 
 
Vorname : __________________________________ 
 
Geschlecht :  O weiblich     O männlich 
 
Geb. Datum : _________________(TT/MM/YYYY) 
 
Gewicht : _______________________________(Kg) 
 
Größe : ______________________________(Meter) 
 
 
Wir bitten Sie, diesen Fragebogen selbständig auszufüllen und vollständig im frankierten 
Briefumschlag an unser Institut zurücksenden. Bitte beantworten möglichst Sie alle 
Fragen (auch wenn eine Frage für Sie nicht zutrifft). Bitte gehen Sie weiter mit den 
anderen Fragen, wenn sich nicht genau die Antwort erinnern können. 
Würden Sie uns bitte einige Angaben zu Ihrer Krankengeschichte machen? 
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Datum der Erstdiagnose Prolaktinom: ________________________ 
 




Normwerte des Labors: _______________ 
Kommentar:  erhöht  O  unauffällig  O nicht bekannt  O 
__________________________________________________________ 
 
MRT bei Erstdiagnose: 
Datum: ___________________ 
Makroadenom    O    Kommentar: ________________________________ 
Mikroadenom     O    Kommentar: ________________________________ 
Unbekannt          O    Kommentar: _______________________________ 
 
Gesichtsfeld bei Erstdiagnose: 
Datum: ___________________ 
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Einheit: ___________ 
Normwerte des Labors:_______________ 




Makroadenom    O    Kommentar: ________________________________ 
Mikroadenom     O    Kommentar: ________________________________ 




eingeschränkt  O              nicht eingeschränkt  O             unbekannt  O 
verbessert zum Vorbefund  O            verschlechtert zum Vorbefund  O 
 
Gewicht: 
Höchstes Gewicht: kg __________ Datum __________ 
Niedrigstes Gewicht: kg __________ Datum __________ 
 
Hatten Sie zu irgendeinem Zeitpunkt vor Diagnose und Therapie des Prolaktinoms eines 
dieser Symptome bemerkt oder vom Arzt diagnostiziert bekommen? 
Bitte kreuzen Sie Zutreffendes an (ggf. mit Beginn). Bitte schätzen Sie zusätzlich den Grad 
der Intension des Symptoms auf einer Skala von 1-5 ein: 
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Intensitätsskala: 
1 = überhaupt nicht vorhanden/ausgeprägt 
2 = wenig ausgeprägt 
3 = mittelgradig ausgeprägt 
4 = stark ausgeprägt 
5 = sehr stark ausgeprägt 
 
 
Symptome JA NEIN Beginn Intensität 
1-2-3-4-5 
Beispiel x  2001 2 
1. Kopfschmerzen     
2. Milchausfluss 
(Galaktorrhoe) 
    
3. Schmerzen der Brüste 
(Mastodynie)  
    
4. Gewichtsabnahme*     
5. Gewichtszunahme*     
6. Reduzierte Libido( = wenig 
Spaß am Sex, kaum Lust auf 
Sexualverkehr) 
    
7. Deutlich gesteigerte 
Libido( = gesteigerter Spaß 
am Sex / Lust auf 
Sexualverkehr) 
    
 - 90 -




    
9. Depressive Verstimmung     
10. Schlafstörung     
11. Müdigkeit     
12. Empfindungsstörungen 
(Parästhesien) 
    
13. Schwindel      
14. Aggressivität      
15. Angst      
16. Visuelle Halluzinationen 
(Wahrnehmungen) 
    
17. Spielsucht     
18. Übermäßiges Einkaufen      
19. Essanfälle     
20. Ausreißen der Haare      
21. Andere Suchterkrankungen 
(ggf. bitte 
eintragen:__________________) 
    
22. Vermehrter Alkoholkonsum     
23. Verminderter 
Alkoholkonsum 
    
24. Andere psychiatrische     
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Erkrankungen / Symptome 
(ggf. bitte 
eintragen:__________________) 
     
Nur für Frauen     
Unregelmäßige 
Periodenblutungen 
    
     
Nur für Männer     
1.Erektile Dysfunktion / 
Impotenz 
    
2.Nachlassender Bartwuchs     
 
* Bitte Angabe der kg ___________ zwischen (Jahr): ____________ und 
(Jahr):_________ 
 
• Brauchten Sie für eine der o. g. Erkrankungen oder Symptome eine Therapie?              
O  Ja          O  Nein 
• Wenn ja, für welche:________________________________________ 
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Erhalten/erhielten Sie eine der folgenden Therapie für Ihre Hyperprolaktinämie/das 
Prolaktinom? 
Bitte füllen Sie die zutreffenden Felder aus. 
 
• Hypophysenoperation                 O  ja       O  nein 
Datum: __________ 
Anzahl: __________ 
Art:   O  transphenoidal        O  transkraniell          O  unbekannt 
 
• Bestrahlung der Hypophyse       O  ja       O  nein 
Datum: __________ 
Art:   O  stereotaktisch fraktionär    O  Gammaknife    O  Cyberknife  
 
• Medikamentöse Therapie 
 
1) Bromocriptin (Handelsnamen: Bromocrel, Bromocriptin-rathiop., Kirim, Parlodel, 
Pravidel) 
O  ja   O  nein 
2) Lisurid (Handelsname: Dopergin) 
O  ja   O  nein 
3) Cabergolin (Handelsnamen: Dostinex – Cabaseril) 
O  ja   O  nein 
4) Quinagolide (Handelsname: Norprolac) 
O  ja   O  nein 
5) Andere medikamentöse Therapie (Handelsname _________________) 
O  ja   O  nein 
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Wenn Sie eine Hypophysenoperation erhielten, ist nach der Operation eines der 
folgenden Symptome neu aufgetreten oder hat sich verändert? 
(Bitte folgende Seite nur ausfüllen, falls Sie diese Therapie erhalten haben) 
Bitte kreuzen Sie Zutreffendes an (ggf. mit Beginn). Bitte schätzen Sie zusätzlich den Grad 




1 = überhaupt nicht vorhanden/ausgeprägt 
2 = wenig ausgeprägt 
3 = mittelgradig ausgeprägt 
4 = stark ausgeprägt 
5 = sehr stark ausgeprägt 
 
 
Symptome Neu Verstärkt Vermindert Unverändert Skala 
1-5 
Beispiel Nein Ja   2 
1. Kopfschmerzen      
2. Milchausfluss 
(Galaktorrhoe) 
     
3. Schmerzen der Brüste 
(Mastodynie)  
     
4. Gewichtsabnahme*      
5. Gewichtszunahme*      
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6. Reduzierte Libido( = wenig 
Spaß am Sex, kaum Lust auf 
Sexualverkehr) 
     
7. Deutlich gesteigerte Libido 
( = gesteigerter Spaß am Sex 
/ Lust auf Sexualverkehr) 
     
8. Verminderte 
Knochendichte (Osteopenie) 
     
9. Depressive Verstimmung      
10. Schlafstörung      
11. Müdigkeit      
12. Empfindungsstörungen 
(Parästhesien) 
     
13. Schwindel       
14. Aggressivität       
15. Angst       
16. Visuelle Halluzinationen 
(Wahrnehmungen) 
     
17. Spielsucht      
18. Übermäßiges Einkaufen       
19. Essanfälle      
20. Ausreißen der Haare 
(Trichotillomanie) 
     
21. Andere Suchterkrankungen 
(ggf. bitte 
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eintragen:__________________) 
22. Vermehrter Alkoholkonsum      
23. Verminderter 
Alkoholkonsum 
     
24. Andere psychiatrische 
Erkrankungen / Symptome 
(ggf. bitte 
eintragen:__________________) 
     
Nur für Frauen      
Unregelmäßige 
Periodenblutungen 
     
      
Nur für Männer      
1.Erektile Dysfunktion / 
Impotenz 
     
2.Nachlassender Bartwuchs      
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Wenn Sie eine Bestrahlung erhielten, ist unter der Bestrahlung eines der folgenden 
Symptome neu aufgetreten oder hat sich verändert? 
(Bitte folgende Seite nur ausfüllen, falls Sie diese Therapie erhalten haben) 
Bitte kreuzen Sie Zutreffendes an (ggf. mit Beginn). Bitte schätzen Sie zusätzlich den Grad 




1 = überhaupt nicht vorhanden/ausgeprägt 
2 = wenig ausgeprägt 
3 = mittelgradig ausgeprägt 
4 = stark ausgeprägt 
5 = sehr stark ausgeprägt 
 
Symptome Neu Verstärkt Vermindert Unverändert Skala 
1-5 
Beispiel Nein Ja   2 
1. Kopfschmerzen      
2. Milchausfluss 
(Galaktorrhoe) 
     
3. Schmerzen der Brüste 
(Mastodynie)  
     
4. Gewichtsabnahme*      
5. Gewichtszunahme*      
6. Reduzierte Libido( = wenig      
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Spaß am Sex, kaum Lust auf 
Sexualverkehr) 
7. Deutlich gesteigerte Libido 
( = gesteigerter Spaß am Sex 
/ Lust auf Sexualverkehr) 
     
8. Verminderte 
Knochendichte (Osteopenie) 
     
9. Depressive Verstimmung      
10. Schlafstörung      
11. Müdigkeit      
12. Empfindungsstörungen 
(Parästhesien) 
     
13. Schwindel       
14. Aggressivität       
15. Angst       
16. Visuelle Halluzinationen 
(Wahrnehmungen) 
     
17. Spielsucht      
18. Übermäßiges Einkaufen       
19. Essanfälle      
20. Ausreißen der Haare 
(Trichotillomanie) 
     
21. Andere Suchterkrankungen 
(ggf. bitte 
eintragen:__________________) 
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22. Vermehrter Alkoholkonsum      
23. Verminderter 
Alkoholkonsum 
     
24. Andere psychiatrische 
Erkrankungen / Symptome 
(ggf. bitte 
eintragen:__________________) 
     
      
Nur für Frauen      
Unregelmäßige 
Periodenblutungen 
     
      
Nur für Männer      
1.Erektile Dysfunktion / 
Impotenz 
     
2.Nachlassender Bartwuchs      
 





1) Wenn Sie diese medikamentöse Therapie (Bromocriptin) erhielten, ist unter der 
Therapie eines der folgenden Symptome neu aufgetreten oder hat sich verändert? 
(Bitte folgende Seite nur ausfüllen, falls Sie diese Therapie erhalten haben) 
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Bromocriptin (Handelsnamen: Bromocrel, Bromocriptin-rathiop., Kirim, Parlodel, 
Pravidel)   O  ja   O  nein 
Beginn: ________________________________________ 
Höchste Dosis: __________________________________ 
Dauer: _________________________________________ 
Aktuell:   O  ja         O  nein 
 
- Therapie senkt/senkte Prolaktin erfolgreich   O  ja   O  nein  O  teilweise 
Prolaktinwert vor ____________und nach Therapie: ______________ 
- Therapie führte zu einer Tumorschrumpfung   O  ja   O  nein  O  teilweise 
Tumordurchmesser vor ____________und nach Therapie: ____________ 
 
Bitte kreuzen Sie Zutreffendes an (ggf. mit Beginn). Bitte schätzen Sie zusätzlich den Grad 




1 = überhaupt nicht vorhanden/ausgeprägt 
2 = wenig ausgeprägt 
3 = mittelgradig ausgeprägt 
4 = stark ausgeprägt 
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Symptome Neu Verstärkt Vermindert Unverändert Skala 
1-5 
Beispiel Nein Ja   2 
1. Kopfschmerzen      
2. Milchausfluss 
(Galaktorrhoe) 
     
3. Schmerzen der Brüste 
(Mastodynie)  
     
4. Gewichtsabnahme*      
5. Gewichtszunahme*      
6. Reduzierte Libido( = wenig 
Spaß am Sex, kaum Lust auf 
Sexualverkehr) 
     
7. Deutlich gesteigerte Libido 
( = gesteigerter Spaß am Sex 
/ Lust auf Sexualverkehr) 
     
8. Verminderte 
Knochendichte (Osteopenie) 
     
9. Depressive Verstimmung      
10. Schlafstörung      
11. Müdigkeit      
12. Empfindungsstörungen 
(Parästhesien) 
     
13. Schwindel       
14. Aggressivität       
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15. Angst       
16. Visuelle Halluzinationen 
(Wahrnehmungen) 
     
17. Spielsucht      
18. Übermäßiges Einkaufen       
19. Essanfälle      
20. Ausreißen der Haare 
(Trichotillomanie) 
     
21. Andere Suchterkrankungen 
(ggf. bitte 
eintragen:__________________) 
     
22. Vermehrter Alkoholkonsum      
23. Verminderter 
Alkoholkonsum 
     
24. Andere psychiatrische 
Erkrankungen / Symptome 
(ggf. bitte 
eintragen:__________________) 
     
      
Nur für Frauen      
Unregelmäßige 
Periodenblutungen 
     
      
Nur für Männer      
1.Erektile Dysfunktion /      
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Impotenz 
2.Nachlassender Bartwuchs      
 
* Bitte Angabe der kg ___________ zwischen (Jahr): ____________ und 
(Jahr):_________ 
 
2) Wenn Sie diese medikamentöse Therapie (Lisurid) erhielten, ist unter der Therapie 
eines der folgenden Symptome neu aufgetreten oder hat sich verändert? 
(Bitte folgende Seite nur ausfüllen, falls Sie diese Therapie erhalten haben) 
 
Lisurid (Handelsname: Dopergin)   O  ja   O  nein 
Beginn: ________________________________________ 
Höchste Dosis: __________________________________ 
Dauer: _________________________________________ 
Aktuell:   O  ja         O  nein 
 
- Therapie senkt/senkte Prolaktin erfolgreich   O  ja   O  nein  O  teilweise 
Prolaktinwert vor ____________und nach Therapie: ______________ 
 
- Therapie führte zu einer Tumorschrumpfung   O  ja   O  nein  O  teilweise 
Tumordurchmesser vor ____________und nach Therapie: ____________ 
 
Bitte kreuzen Sie Zutreffendes an (ggf. mit Beginn). Bitte schätzen Sie zusätzlich den Grad 
der Intension des Symptoms auf einer Skala von 1-5 ein: 
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Intensitätsskala: 
 
1 = überhaupt nicht vorhanden/ausgeprägt 
2 = wenig ausgeprägt 
3 = mittelgradig ausgeprägt 
4 = stark ausgeprägt 
5 = sehr stark ausgeprägt 
 
Symptome Neu Verstärkt Vermindert Unverändert Skala 
1-5 
Beispiel Nein Ja   2 
1. Kopfschmerzen      
2. Milchausfluss 
(Galaktorrhoe) 
     
3. Schmerzen der Brüste 
(Mastodynie)  
     
4. Gewichtsabnahme*      
5. Gewichtszunahme*      
6. Reduzierte Libido( = wenig 
Spaß am Sex, kaum Lust auf 
Sexualverkehr) 
     
7. Deutlich gesteigerte Libido 
( = gesteigerter Spaß am Sex 
/ Lust auf Sexualverkehr) 
     
8. Verminderte      
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Knochendichte (Osteopenie) 
9. Depressive Verstimmung      
10. Schlafstörung      
11. Müdigkeit      
12. Empfindungsstörungen 
(Parästhesien) 
     
13. Schwindel       
14. Aggressivität       
15. Angst       
16. Visuelle Halluzinationen 
(Wahrnehmungen) 
     
17. Spielsucht      
18. Übermäßiges Einkaufen       
19. Essanfälle      
20. Ausreißen der Haare 
(Trichotillomanie) 
     
21. Andere Suchterkrankungen 
(ggf. bitte 
eintragen:__________________) 
     
22. Vermehrter Alkoholkonsum      
23. Verminderter 
Alkoholkonsum 
     
24. Andere psychiatrische 
Erkrankungen / Symptome 
(ggf. bitte 
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eintragen:__________________) 
      
Nur für Frauen      
Unregelmäßige 
Periodenblutungen 
     
      
Nur für Männer      
1.Erektile Dysfunktion / 
Impotenz 
     
2.Nachlassender Bartwuchs      
 
* Bitte Angabe der kg ___________ zwischen (Jahr): ____________ und 
(Jahr):_________ 
 
3) Wenn Sie diese medikamentöse Therapie (Cabergolin) erhielten, ist unter der 
Therapie eines der folgenden Symptome neu aufgetreten oder hat sich verändert?  
(Bitte folgende Seite nur ausfüllen, falls Sie diese Therapie erhalten haben) 
 
Cabergolin (Handelsnamen: Dostinex – Cabaseril)   O  ja   O  nein 
Beginn: ________________________________________ 
Höchste Dosis: __________________________________ 
Dauer: _________________________________________ 
Aktuell:   O  ja         O  nein 
 
- Therapie senkt/senkte Prolaktin erfolgreich   O  ja   O  nein  O  teilweise 
Prolaktinwert vor ____________und nach Therapie: ______________ 
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- Therapie führte zu einer Tumorschrumpfung   O  ja   O  nein  O  teilweise 
Tumordurchmesser vor ____________und nach Therapie: ____________ 
 
Bitte kreuzen Sie Zutreffendes an (ggf. mit Beginn). Bitte schätzen Sie zusätzlich den Grad 




1 = überhaupt nicht vorhanden/ausgeprägt 
2 = wenig ausgeprägt 
3 = mittelgradig ausgeprägt 
4 = stark ausgeprägt 
5 = sehr stark ausgeprägt 
 
Symptome Neu Verstärkt Vermindert Unverändert Skala 
1-5 
Beispiel Nein Ja   2 
1. Kopfschmerzen      
2. Milchausfluss 
(Galaktorrhoe) 
     
3. Schmerzen der Brüste 
(Mastodynie)  
     
4. Gewichtsabnahme*      
5. Gewichtszunahme*      
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6. Reduzierte Libido( = wenig 
Spaß am Sex, kaum Lust auf 
Sexualverkehr) 
     
7. Deutlich gesteigerte Libido 
( = gesteigerter Spaß am Sex 
/ Lust auf Sexualverkehr) 
     
8. Verminderte 
Knochendichte (Osteopenie) 
     
9. Depressive Verstimmung      
10. Schlafstörung      
11. Müdigkeit      
12. Empfindungsstörungen 
(Parästhesien) 
     
13. Schwindel       
14. Aggressivität       
15. Angst       
16. Visuelle Halluzinationen 
(Wahrnehmungen) 
     
17. Spielsucht      
18. Übermäßiges Einkaufen       
19. Essanfälle      
20. Ausreißen der Haare 
(Trichotillomanie) 
     
21. Andere Suchterkrankungen 
(ggf. bitte 
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eintragen:__________________) 
22. Vermehrter Alkoholkonsum      
23. Verminderter 
Alkoholkonsum 
     
24. Andere psychiatrische 
Erkrankungen / Symptome 
(ggf. bitte 
eintragen:__________________) 
     
      
Nur für Frauen      
Unregelmäßige 
Periodenblutungen 
     
      
Nur für Männer      
1.Erektile Dysfunktion / 
Impotenz 
     
2.Nachlassender Bartwuchs      
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4) Wenn Sie diese medikamentöse Therapie (Quinagolide) erhielten, ist unter der 
Therapie eines der folgenden Symptome neu aufgetreten oder hat sich verändert?  
(Bitte Seite nur ausfüllen, falls Sie diese Therapie erhalten haben) 
 
Quinagolide (Handelsname: Norprolac)  O  ja   O  nein 
Beginn: ________________________________________ 
Höchste Dosis: __________________________________ 
Dauer: _________________________________________ 
Aktuell:   O  ja         O  nein 
 
- Therapie senkt/senkte Prolaktin erfolgreich   O  ja   O  nein  O  teilweise 
Prolaktinwert vor ____________und nach Therapie: ______________ 
 
- Therapie führte zu einer Tumorschrumpfung   O  ja   O  nein  O  teilweise 
Tumordurchmesser vor ____________und nach Therapie: ____________ 
 
Bitte kreuzen Sie Zutreffendes an (ggf. mit Beginn). Bitte schätzen Sie zusätzlich den Grad 




1 = überhaupt nicht vorhanden/ausgeprägt 
2 = wenig ausgeprägt 
3 = mittelgradig ausgeprägt 
4 = stark ausgeprägt 
5 = sehr stark ausgeprägt 
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Symptome Neu Verstärkt Vermindert Unverändert Skala 
1-5 
Beispiel Nein Ja   2 
1. Kopfschmerzen      
2. Milchausfluss 
(Galaktorrhoe) 
     
3. Schmerzen der Brüste 
(Mastodynie)  
     
4. Gewichtsabnahme*      
5. Gewichtszunahme*      
6. Reduzierte Libido( = wenig 
Spaß am Sex, kaum Lust auf 
Sexualverkehr) 
     
7. Deutlich gesteigerte Libido 
( = gesteigerter Spaß am Sex 
/ Lust auf Sexualverkehr) 
     
8. Verminderte 
Knochendichte (Osteopenie) 
     
9. Depressive Verstimmung      
10. Schlafstörung      
11. Müdigkeit      
12. Empfindungsstörungen 
(Parästhesien) 
     
13. Schwindel       
14. Aggressivität       
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15. Angst       
16. Visuelle Halluzinationen 
(Wahrnehmungen) 
     
17. Spielsucht      
18. Übermäßiges Einkaufen       
19. Essanfälle      
20. Ausreißen der Haare 
(Trichotillomanie) 
     
21. Andere Suchterkrankungen 
(ggf. bitte 
eintragen:__________________) 
     
22. Vermehrter Alkoholkonsum      
23. Verminderter 
Alkoholkonsum 
     
24. Andere psychiatrische 
Erkrankungen / Symptome 
(ggf. bitte 
eintragen:__________________) 
     
      
Nur für Frauen      
Unregelmäßige 
Periodenblutungen 
     
      
Nur für Männer      
1.Erektile Dysfunktion /      
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Impotenz 
2.Nachlassender Bartwuchs      
 
* Bitte Angabe der kg ___________ zwischen (Jahr): ____________ und 
(Jahr):_________ 
 
5) Wenn Sie eine andere medikamentöse Therapie erhielten, ist unter der Therapie eine 
der folgenden Symptome neu aufgetreten oder hat sich verändert?  
(Bitte Seite nur ausfüllen, falls Sie diese Therapie erhalten haben) 
 
Andere medikamentöse Therapie des Prolaktinoms     O  ja     O  nein 
(Handelsnamen: __________________________) 
Beginn: ________________________________________ 
Höchste Dosis: __________________________________ 
Dauer: _________________________________________ 
Aktuell:   O  ja         O  nein 
 
- Therapie senkt/senkte Prolaktin erfolgreich   O  ja   O  nein  O  teilweise 
Prolaktinwert vor ____________und nach Therapie: ______________ 
 
- Therapie führte zu einer Tumorschrumpfung   O  ja   O  nein  O  teilweise 
Tumordurchmesser vor ____________und nach Therapie: ____________ 
 
Bitte kreuzen Sie Zutreffendes an (ggf. mit Beginn). Bitte schätzen Sie zusätzlich den Grad 
der Intension des Symptoms auf einer Skala von 1-5 ein: 
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Intensitätsskala: 
 
1 = überhaupt nicht vorhanden/ausgeprägt 
2 = wenig ausgeprägt 
3 = mittelgradig ausgeprägt 
4 = stark ausgeprägt 
5 = sehr stark ausgeprägt 
 
Symptome Neu Verstärkt Vermindert Unverändert Skala 
1-5 
Beispiel Nein Ja   2 
1. Kopfschmerzen      
2. Milchausfluss 
(Galaktorrhoe) 
     
3. Schmerzen der Brüste 
(Mastodynie)  
     
4. Gewichtsabnahme*      
5. Gewichtszunahme*      
6. Reduzierte Libido( = wenig 
Spaß am Sex, kaum Lust auf 
Sexualverkehr) 
     
7. Deutlich gesteigerte Libido 
( = gesteigerter Spaß am Sex 
/ Lust auf Sexualverkehr) 
     
8. Verminderte      
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Knochendichte (Osteopenie) 
9. Depressive Verstimmung      
10. Schlafstörung      
11. Müdigkeit      
12. Empfindungsstörungen 
(Parästhesien) 
     
13. Schwindel       
14. Aggressivität       
15. Angst       
16. Visuelle Halluzinationen 
(Wahrnehmungen) 
     
17. Spielsucht      
18. Übermäßiges Einkaufen       
19. Essanfälle      
20. Ausreißen der Haare 
(Trichotillomanie) 
     
21. Andere Suchterkrankungen 
(ggf. bitte 
eintragen:__________________) 
     
22. Vermehrter Alkoholkonsum      
23. Verminderter 
Alkoholkonsum 
     
24. Andere psychiatrische 
Erkrankungen / Symptome 
(ggf. bitte 
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eintragen:__________________) 
      
Nur für Frauen      
Unregelmäßige 
Periodenblutungen 
     
      
Nur für Männer      
1.Erektile Dysfunktion / 
Impotenz 
     
2.Nachlassender Bartwuchs      
 
* Bitte Angabe der kg ___________ zwischen (Jahr): ____________ und 
(Jahr):_________ 
 
Noch einige allgemeine Angabe: 
 
Nur für Frauen 
 
• Sind Sie derzeit in den Wechseljahren?          O  ja       O  nein 
• Wenn Sie das Klimakterium bereits hinter sich haben, wann war Ihre letzte 
Regelblutung? (Menopause) : mit _______ Jahren 
• Wann war Ihre erste Regelblutung? (Menarche) : mit _______ Jahren 
• Gibt/ gab es Besonderheiten der Regel?          O  ja       O  nein 
• Haben Sie eigene Kinder?     O  ja         O  nein      Wie viele? ____  
• Aborte ________. wann ________(Jahr) 
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Nur für Männer 
 
• Haben Sie eigene Kinder?     O  ja         O  nein      Wie viele? ____ 
 
Nehmen oder nahmen Sie jemals regelmäßig andere Medikamente ein?  
Liste aller regelmäßig eingenommenen Medikamente (unabhängig von 
Prolaktinombehandlung) mit Zeitraum und Diagnose 
(Für Frauen und Männer) 
 








(Für Frauen und Männer) 
 
Leiden oder litten Sie an folgenden Erkrankungen? 
 
1) Kardiovaskuläre Erkrankungen (Herzkreislauferkrankungen) 
1a) Arrhythmien (Herzrhythmusstörungen)                        O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
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Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
1b) Kardiomyopathie (Herzrmuskelerkrankung)                O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
1c) Cerebrovaskuläre Erkrankungen (Erkrankungen der Hirngefäße)  
O Ja       O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
1d) Hypertonus (Bluthochdruck)                                        O Ja       O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
1e) KHK (Koronare Herzerkrankung)                               O Ja       O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
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Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
1f) Myokardinfarkt (Herzinfarkt)                                        O Ja       O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
2) Erkrankungen des Bewegungsapparats 
2a) Arthralgie (Gelenkschmerzen)                                      O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
2b) Arthropathie (Gelenkerkrankungen)                             O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
2c) Karpaltunnelssyndrom Arthropathie (Gelenkerkrankungen) 
O Ja     O Nein                                    
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
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Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
3) Metabolische Erkrankung 
3a) Diabetes mellitus (Zuckerkrankheit)                             O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
3b) Hypophyseninsuffizienz                                                 O Ja      O Nein 
Insuffizienz der: 
-corticotrope Achse (Substitution mit Hydrocortison)    O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
-thyreotrope Achse (Substitution mit Schilddrüsenhormon) O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
-gonadotrope Achse (Substitution mit Sexualhormonen)     O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
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Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
-somatotrope Achse (Substitution mit Wachstumshormon)  O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
4) Respiratorische Erkrankungen (Erkrankungen der Atemwege) 
4a) Schlafapnoesyndrom                                                       O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
 
4b) Andere Lungenerkrankungen                                          O Ja      O Nein 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 




Krebserkrankungen                                                                O Ja      O Nein 
Wenn ja, welche:_____________________________________ 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
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Therapie:     O Ja    O Nein 
Therapie: ______________________________________________ 
Spezifikationen: _________________________________________ 
6) Psychiatrische Erkrankungen                                        O Ja      O Nein 
Wenn ja, welche:_____________________________________ 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 




7) Sonstige Erkrankungen                                                 O Ja      O Nein 
Wenn ja, welche:_____________________________________ 
Dauer: ______________________ 
Derzeit:        O Ja    O Nein 
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(Für Frauen und Männer) 
• Sind Sie derzeit:  
O berufstätig                 O  arbeitslos                  O sonstiges _________ 
O Rentner/Rentnerin     O Hausfrau 
• Ihr Familienstand ist: O  ledig      O  verheiratet      O  geschieden/verwitwet 
• Wie viele Jahre sind Sie zu Schule gegangen?      _______ Jahre 
• Rauchen Sie zur Zeit täglich Zigaretten oder haben Sie früher täglich Zigaretten 
geraucht? 
O Nein, ich habe noch nie Zigaretten geraucht 
O Ja, ich rauche seit ____ Jahren täglich etwa ____ Zigaretten 
O Ja, ich habe früher täglich geraucht. Insgesamt ____ Jahren und ca. ____ Zigaretten pro 
Tag. 
• Wie oft trinken Sie Alkoholika (Bier, Wein, Likör, Spirituosen)? 
O täglich oder fast täglich (5-7 mal pro Woche) 
O gelegentlich (3-4 mal pro Woche) 
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O selten (1-2 mal pro Woche) 
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12.2 DNA preparation and genotyping 
 
Primer F rs1045642MP_F GCTGAGAACATTGCCTATGGA 
Primer R rs1045642MP_R CTCTTCACTTCTGGGAAACC 
Sonde sensor rs1045642MP_FL GATCGTGAGGGCAGCAAAGGAG-Fluorescein 
Sonde anchor rs1045642MP_LC LC Red 610-CAACATACATGCCTTCATCGAGTCACTGCC-Phosphate 
Primer F rs2032582MP_F TGTTACTCTTAGCAATTGTACCCATC 
Primer R rs2032582MP_R AAACACATTCTTAGAGCATAGTAAGC 





Primer F rs2235015MP_F ACACAATTAAAACTGAGTCAGTTCG 





Sonde anchor rs2235015MP_FL AACCCTGTATCATTGATATCACCTAGACCACCAC-Fluorescein 
Primer F rs2032583MP_F AGAAAGAACTAGAAGGTTCTGGG 
Primer R rs2032583MP_R TTGAGTCCAAGAACTGGCT 
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Light Cycler 480 Multiplex: Genotyping Master  
    
  Number of probes 1  
Mix:      
Component 
Concentration 
Stock Capillary concentration µl / Reaction  µl for probes 
Water     4,00 4,40 
MgCl2 25000 0,0 0,00 0,00 
Primer forward A 10 0,5 0,50 0,55 
Primer reverse A 10 0,5 0,50 0,55 
Primer forward B 10 0,5 0,50 0,55 
Primer reverse B 10 0,5 0,50 0,55 
Fluos HybProbe A 4 0,2 0,50 0,55 
Light Cycler Red 610 HybProbeA 4 0,2 0,50 0,55 
Fluos HybProbe B 4 0,2 0,50 0,55 
Light Cycler Red 640 HybProbeB 4 0,2 0,50 0,55 
Enzyme Mix (Genotyping Master) 5 1 2,00 2,20 
  Total: 10,00 11 
     
µl Mix 9    
µl cDNA 1    
 
LightCycler® 480 Genotyping Master  
Ready-to-use hot start reaction mix for real-time PCR and probe melting-curve based genotyping using the 
LightCycler® 480 Instrument. 
Artikelnr.: 04707524001 ? 4 x 384 µl 5x conc. approx. 384 reactions of 20 µl reaction volume each. 
 
Application: 
The LightCycler® 480 Genotyping Master is designed to easily perform real-time PCR followed by genotyping 
via melting curves on the LightCycler® 480 Instrument. It can be used to genotype single nucleotide 
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polymorphisms (SNPs) and to perform mutation analysis, and is especially recommended for multiplex 
approaches. The LightCycler® 480 Genotyping Master can be used for the amplification and detection of every 
DNA or cDNA target. Only template DNA, primers, and suitable sequence-specific probes (HybProbe probes or 
SimpleProbe probes) have to be added. 
 
Product description: 
The LightCycler® 480 Genotyping Master is a hot start reaction mix for PCR. The supplied enzyme contains a 
5'-3'-exo-minus, N-terminal deletion of thermostable recombinant Taq DNA polymerase that is inactive at room 
temperature due to a chemical modification, and becomes activated during a 10-minute incubation at 95°C. 
HybProbe probes or SimpleProbe probes are used as detection format during PCR and subsequent melting curve 
analysis. 
Since the mix is provided as a one-component, easy-to-use reagent, reaction setup only requires the addition of 
template DNA and primers. The mix can be used with different types of DNA (e.g., genomic, cDNA), and is 
ideally suited for high-throughput applications in 96- or 384-well plates. 
 
Hybridisation Probes (Hybprobes): Monitor PCR with the LightCycler® HybProbe Format 
The unique LightCycler® HybProbe format is based on fluorescence resonance energy transfer (FRET). Two 
sequence-specific oligonucleotide probes are labeled with different dyes (donor and acceptor), and are added to 
the reaction mix along with the PCR primers. During the annealing phase, HybProbe probes hybridize to the 
target sequences on the amplified DNA fragment in a head-to-tail arrangement, thereby bringing the two dyes 
close to each other. The donor dye (fluorescein) is excited by the blue LED. As long as the two dyes are close to 
each other (within 15 nucleotides), the energy emitted by the donor dye excites the acceptor dye on the second 
HybProbe probe, which then emits fluorescent light at a different wavelength. This fluorescence is directly 
proportional to the amount of target DNA generated during PCR. HybProbe probes are displaced during the 
elongation and denaturation steps. 
 
Advantages of the HybProbe Format 
• Only the presence of a specific amplification product causes an increase in fluorescence  
• Increased specificity, because two sequence-specific probes hybridize to the target  
• Primer-dimers do not interfere, because the sequence-specific probes do not recognize them  
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• Probe sequences are not altered by PCR, so they can still be used in a subsequent assay, e.g., for 
mutation detection or SNP analysis  
 
A The donor-dye probe is labelled with fluorescein at the 3´ end and the 
acceptor-dye probe is labelled with LightCycler® Red at the 5´ end. 
Hybridization does not take place during the denaturation phase of PCR 
and, thus, the distance between the dyes is too large to allow energy 
transfer to occur. 
B During the annealing phase, the probes hybridize to the amplified DNA 
fragment in a close head-to-tail arrangement. When fluorescein is excited by the 
light from the LED, it emits green 
fluorescent light, transferring the energy to LightCycler® Red, which then emits 
red fluorescent light. This red fluorescence is measured at the end of each 
annealing step, when the fluorescence intensity is highest. 
C After annealing, the temperature is raised and the HybProbe probe is displaced 
during elongation. At the end of this step, the PCR product is double-stranded 
and the displaced HybProbe probes are again too far apart to allow FRET to 
occur. 
 
DNA Purification Protocol for 2ml Saliva Samples 
 
Cell Lysis 
1. Incubate Oragene•DNA/Saliva samples at 50ºC in a water incubator for a minimum of 1 hour or in an air 
incubator for a minimum of 2 hours. 
2. Transfer 4 ml lysate sample (2 ml saliva plus 2 ml Oragene•DNA-preserving solution) to a 15 or 50 ml 
centrifuge tube. 
3. Add 1 ml Cell Lysis Solution and 25 μl Gentra RNase A Solution (4 mg/ml). Vortex on high speed for 10 
seconds to mix sample and incubate 10 minutes at room temperature. 
Protein Precipitation 
4. Add 1.67 ml Protein Precipitation Solution to the cell lysate. 
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5. Vortex vigorously at high speed for 20 seconds to mix the Protein Precipitation Solution uniformly with the 
cell lysate. 
6. Centrifuge at 2,000 x g for 5 minutes. The precipitated proteins will form a tight dark brown pellet. If the 
protein pellet is not tight, repeat Step 4 followed by incubation on ice for 5 minutes and then repeat Step 5. 
DNA Precipitation 
7. Pour the supernatant containing the DNA (leaving behind the precipitated protein pellet) into a 15 or 50 ml 
tube containing 5 ml 100% Isopropanol (2-propanol) and 40 μl of Gentra Glycogen Solution (20 mg/ml). 
8. Mix the sample by inverting gently 50 times. 
9. Centrifuge at 2,000 x g for 3 minutes; the DNA will be visible as a small white pellet. 
10. Pour off supernatant and drain tube briefly on clean absorbent paper. Add 5 ml 70% Ethanol and invert tube 
several times to wash the DNA pellet. 
11. Centrifuge at 2,000 x g for 1 minute. Carefully pour off the ethanol. Pellet may be loose so pour slowly and 
watch pellet. 
12. Invert and drain the tube on clean absorbent paper and allow sample to air dry 5-10 minutes. 
DNA Hydration 
13. Add 400 μl DNA Hydration Solution (400 μl will give a concentration of 200 μg/ml if the total yield is 80 μg 
DNA). 
14. Rehydrate DNA by incubating at 65°C for 1 hour and overnight at room temperature. If possible, tap tube 
periodically to aid in dispersing the DNA. 
15. For storage, sample may be centrifuged briefly and then transferred to a 1.5 ml tube. Store DNA at 4°C. For 
long-term storage, store at -20°C or -80°C. 
 
 
